Bridging compounds as agonists of muscarinic M1 and / or M4 receptors
By designing bridging morpholine compounds with highly selective M1 and/or M4 receptor agonists, the problems of insufficient selectivity and large side effects of existing muscarinic acetylcholine receptor agonists in the treatment of Alzheimer's disease, schizophrenia, and pain have been solved, achieving more effective and safer therapeutic results.
Patent Information
- Application Number
- CN201980054903.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-06-22
- Filing Date
- 2019-06-24
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-06-24
AI Technical Summary
Existing muscarinic acetylcholine receptor agonists have problems with insufficient selectivity and significant side effects in the treatment of Alzheimer's disease, schizophrenia and pain, especially with insufficient selectivity for M1 and M4 receptors, which leads to limited therapeutic effects and greater side effects.
A new class of bridging morpholine compounds has been developed. These compounds have highly selective agonist activity against M1 and/or M4 receptors. Through specific chemical structure design, the agonistic effect on M2 and M3 receptors is reduced, thereby reducing side effects.
It improves the selectivity and effectiveness of treatments for Alzheimer's disease, schizophrenia, and pain, reduces side effects, and provides safer treatment options.
Smart Images

Figure CN112585143B_ABST
Abstract
Description
[0001] The present invention relates to a class of novel bridged morpholine compounds, their salts, pharmaceutical compositions comprising them and their use in human therapy. In particular, the present invention relates to a class of compounds which are agonists of muscarinic M1 and / or M4 receptors and are therefore useful in the treatment of Alzheimer's disease, schizophrenia, cognitive disorders and other diseases mediated by muscarinic M1 receptors / M4 receptors, as well as the treatment or relief of pain. Background of the Invention
[0003] Muscarinic acetylcholine receptor (mAChR) is a member of the G protein-coupled receptor superfamily that mediates the effects of the neurotransmitter acetylcholine in both the central nervous system and the peripheral nervous system. Five mAChR subtypes (M1 to M5) have been cloned. M1 mAChR is mainly expressed postsynaptically in the cortex, hippocampus, striatum and thalamus; M2 mAChR is mainly located in the brainstem and thalamus, but is also located in the cortex, hippocampus and striatum, in which M2 mAChR is present on cholinergic synaptic terminals (Langmead et al., 2008 Br J Pharmacol). However, M2 mAChR is also expressed peripherally on cardiac tissue (M2 mAChR mediates the innervation of the vagus nerve of the heart in cardiac tissue) and is expressed peripherally in smooth muscle and exocrine glands. M3 mAChRs are expressed at relatively low levels in the CNS, but are widely expressed in smooth muscle and glandular tissues such as sweat and salivary glands (Langmead et al., 2008 Br J Pharmacol).
[0004] Muscarinic receptors in the central nervous system, particularly M1 mAChR, play a key role in mediating higher cognitive processing. Diseases associated with cognitive impairment, such as Alzheimer's disease, are accompanied by the loss of cholinergic neurons in the basal forebrain (Whitehouse et al., 1982 Science). In schizophrenia, which is also characterized by cognitive impairment, mAChR density is reduced in the prefrontal cortex, hippocampus, and caudate putamen of schizophrenia subjects (Dean et al., 2002 Mol Psychiatry). In addition, in animal models, blocking or damage of central cholinergic pathways leads to significant cognitive deficits, and non-selective mAChR antagonists have been shown to induce psychotomimetic effects in patients with mental illness. Cholinergic replacement therapy is largely based on the use of acetylcholinesterase inhibitors to prevent the decomposition of endogenous acetylcholine. These compounds have shown efficacy against symptomatic cognitive impairment in the clinic, but produce dose-limiting side effects caused by stimulation of peripheral M2 and M3 mAChRs, including gastrointestinal motility disturbances, bradycardia, nausea and vomiting (http: / / www.drugs.com / pro / donepezil.html; http: / / www.drugs.com / pro / rivastigmine.html).
[0005] Additional discovery work is devoted to identifying direct M1 mAChR agonists that target an increase in cognitive function. Such work has led to the identification of a series of agonists, exemplified by compounds such as xanomeline, AF267B, sabcomeline, milameline, and cevimeline. Many of these compounds have been shown to be highly effective in preclinical cognitive models of both rodents and / or non-human primates. Milameline has been shown to have efficacy in rodents in terms of working and spatial memory relative to scopolamine-induced deficits; sabcomeline has demonstrated efficacy in marmosets in visual object discrimination tasks, and xanomeline reverses cognitive performance deficits induced by mAChR antagonists in a passive avoidance paradigm.
[0006] Alzheimer's disease (AD) is the most common neurodegenerative disorder affecting the elderly (26.6 million people worldwide in 2006), leading to severe memory loss and cognitive dysfunction. The etiology of the disease is complex, but is characterized by two hallmark brain sequelae: aggregates of amyloid plaques mainly comprising amyloid-β peptides (Aβ) and neurofibrillary tangles formed by hyperphosphorylated tau proteins. The accumulation of Aβ is considered to be the main feature in the progression of AD, and therefore, many putative therapies for the treatment of AD are currently aimed at inhibiting Aβ production. Aβ is derived from the proteolytic cleavage of membrane-bound amyloid precursor protein (APP). APP is processed by two routes of non-amyloidogenic and amyloidogenic. Cleavage of APP by γ-secretase is common to both pathways, but in the former, APP is cleaved by α-secretase to produce soluble APPα. The cleavage site is within the Aβ sequence, thereby preventing its formation. However, in the amyloidogenic route, APP is cleaved by β-secretase to produce soluble APPβ and also Aβ. In vitro studies have shown that mAChR agonists can promote APP to be processed towards soluble, non-amyloidogenic pathways. In vivo studies have shown that mAChR agonist AF267B changes disease-like pathology in 3xTgAD transgenic mice, a model of different stages (component) of Alzheimer's disease (Caccamo et al., 2006 Neuron). Finally, mAChR agonist Cevimeline has been shown to give a small but significant reduction in Aβ cerebrospinal fluid levels in Alzheimer's patients, thus confirming potential disease-modifying efficacy (Nitsch et al., 2000 Neurol).
[0007] In addition, preclinical studies have shown that mAChR agonists exhibit atypical antipsychotic profiles in a series of preclinical paradigms. The mAChR agonist xanomeline reverses the behavior of multiple dopamine drives, including the movement induced by amphetamine in rats, the climbing induced by apomorphine in mice, the flipping driven by dopamine agonists in rats with unilateral 6-OH-DA damage, and the amphetamine-induced movement in monkeys (without EPS susceptibility). mAChR agonists have also been shown to inhibit dopamine cell discharge and conditioned avoidance of A10 rather than A9, and induce c-fos expression in the prefrontal cortex and nucleus accumbens of rats rather than in the striatum. These data all show atypical antipsychotic profiles (Mirza et al., 1999 CNS Drug Rev). Muscarinic receptors have also been involved in the neurobiology of addiction. The reinforcing effects of cocaine and other addictive substances are mediated by the mesolimbic dopamine system, where behavioral and neurochemical studies have shown that cholinergic muscarinic receptor subtypes play an important role in the regulation of dopaminergic neurotransmission. For example, M(4)(- / -) mice exhibit significantly enhanced reward-driven behaviors due to exposure to cocaine (Schmidt et al. Psychopharmacology (2011) Aug; 216(3): 367-78). In addition, xanomeline has been shown to block the effects of cocaine in these models.
[0008] Muscarinic receptors are also involved in the control of movement and may represent novel treatments for movement disorders such as Parkinson's disease, ADHD, Huntington's disease, Tourette syndrome, and other syndromes associated with dopaminergic dysfunction as an underlying pathogenic factor driving the disease.
[0009] Xanomeline, sabcomeline, miramemline and cevimeline have all progressed to different stages of clinical development for the treatment of Alzheimer's disease and / or schizophrenia. Phase II clinical studies using xanomeline have confirmed the effectiveness of xanomeline relative to a variety of cognitive symptom domains, including behavioral disturbances and hallucinations associated with Alzheimer's disease (Bodick et al., 1997 Arch Neurol). This compound has also been evaluated in a small Phase II study of schizophrenia patients, and when compared with placebo controls, a significant reduction in positive and negative symptoms is given (Shekhar et al., 2008 Am J Psych). However, in all clinical studies, xanomeline and other related mAChR agonists have shown unacceptable safety limits regarding cholinergic side effects, including nausea, gastrointestinal pain, diarrhea, sweating (excessive sweating), hypersalivation (excessive saliva secretion), syncope and bradycardia.
[0010] Muscarinic receptors are involved in central pain and peripheral pain. Pain can be divided into three different types: acute, inflammatory and neuropathic. Acute pain plays an important protective function in keeping the organism safe from stimulation that may cause tissue damage, but requires the management of postoperative pain. Inflammatory pain can occur for many reasons including tissue damage, autoimmune response and pathogen invasion, and is triggered by the effects of inflammatory mediators such as neuropeptides and prostaglandins that cause neuronal inflammation and pain. Neuropathic pain is associated with abnormal pain sensation to non-painful stimuli. Neuropathic pain is associated with many different diseases / traumas, such as spinal cord injury, multiple sclerosis, diabetes (diabetic neuropathy), viral infections (such as HIV or herpes). Due to the side effects of disease or chemotherapy, neuropathic pain is also common in cancer. The activation of muscarinic receptors has been shown to be analgesic in many pain states by activating receptors in the higher pain centers in the spinal cord and the brain. Increasing endogenous acetylcholine levels by acetylcholinesterase inhibitors, directly activating muscarinic receptors with agonists or allosteric modulators have been shown to have analgesic activity. In contrast, blocking muscarinic receptors with antagonists or using knockout mice increases pain sensitivity. Evidence for a role of the M1 receptor in pain is reviewed by DF Fiorino and M. Garcia-Guzman, 2012.
[0011] Recently, a small number of compounds have been identified that exhibit improved selectivity for the M1 mAChR subtype relative to peripherally expressed mAChR subtypes (Bridges et al., 2008 Bioorg Med Chem Lett; Johnson et al., 2010 Bioorg Med Chem Lett; Budzik et al., 2010 ACS Med Chem Lett). Despite the increased level of selectivity relative to the M3 mAChR subtype, some of these compounds retain significant agonist activity with respect to both this subtype and the M2 mAChR subtype. Herein, we describe a series of compounds that unexpectedly exhibit high levels of selectivity for the M1 and / or M4 mAChRs relative to the M2 and M3 receptor subtypes.
[0012] invention
[0013] The present invention provides compounds having activity as muscarinic M1 and / or M4 receptor agonists. More particularly, the present invention provides compounds that exhibit selectivity for the M1 or M4 receptor relative to the M2 and M3 receptor subtypes.
[0014] Therefore, in a first embodiment (Embodiment 1.1), the present invention provides a compound of formula (1):
[0015]
[0016] or a salt thereof, wherein:
[0017] R 1 Selected from NR 5 R 6 ;CONR 8 R 9 an optionally substituted 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof; or R 1 With R 2 connected to form an optionally substituted spirocyclic group;
[0018] R 2 is selected from hydrogen; fluorine; cyano; hydroxyl; amino; and C optionally substituted by one to six fluorine atoms 1-3 A non-aromatic hydrocarbon group, wherein one of the carbon atoms of the hydrocarbon group may be optionally replaced by a heteroatom selected from O, N and S and their oxidized forms, or R 2 With R 1 connected to form an optionally substituted spirocyclic group;
[0019] R 4 is H or C optionally substituted by one to six fluorine atoms 1-6 a non-aromatic hydrocarbon group, wherein one or two but not all carbon atoms of the hydrocarbon group may be optionally replaced by heteroatoms selected from O, N and S and oxidized forms thereof;
[0020] R 5 It is COR 7 , optionally substituted by one or more fluorine atoms or optionally substituted by a non-aromatic C 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms 1-6 A hydrocarbon group; or R 5 Can be used with R 6 joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms;
[0021] R 6 is hydrogen, optionally substituted by one or more fluorine atoms or a non-aromatic C optionally substituted by a 5-membered or 6-membered optionally substituted ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms 1-6 A hydrocarbon group; or R 6 Can be used with R 5 or R 7joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms;
[0022] R 7 is a non-aromatic C optionally substituted by one or more fluorine atoms 1-6 A hydrocarbon group, or R 7 Can be used with R 6 joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms;
[0023] R 8 is hydrogen, optionally substituted by one or more fluorine atoms, a non-aromatic C 1-6 A hydrocarbon group, or R 8 Can be used with R 9 joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms; and
[0024] R 9 is a non-aromatic C optionally substituted by one or more fluorine atoms 1-6 A hydrocarbon group, or R 9 Can be used with R 8 Joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms.
[0025] Specific compounds of formula (1) are further defined according to the following embodiments:
[0026] 1.2. Compounds according to Embodiment 1.1, wherein R 1 YesNR 5 R 6 ;CONR 8 R 9 ; an optionally substituted 5- or 6-membered ring containing 1 or 2 heteroatoms selected from O or N; or R 1 With R 2 are connected to form an optionally substituted spiro ring having 3, 4 or 5 atoms including 0, 1 or 2 heteroatoms selected from O or N.
[0027] 1.3 Compounds according to Embodiment 1.2, wherein R 1 YesNR 5 R 6 or CONR 8 R 9 .
[0028] 1.4 Compounds according to Embodiment 1.2, wherein R 1 With R 2 are connected to form an optionally substituted spiro ring having 3, 4 or 5 atoms including 0, 1 or 2 heteroatoms selected from O or N.
[0029] 1.5. Compounds according to Embodiment 1.4, wherein R 1 With R 2 connected to form an optionally substituted spiro ring having 3, 4 or 5 atoms comprising 0, 1 or 2 heteroatoms selected from O or N, wherein the optional substituents are selected from C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, oxo, hydroxyl or amino or another fused ring.
[0030] 1.6. Compounds according to Embodiment 1.2, wherein R 1 is an optionally substituted 5- or 6-membered ring containing 1 or 2 heteroatoms selected from O or N.
[0031] 1.7. Compounds according to Embodiment 1.6, wherein R 1 is an optionally substituted 5- or 6-membered aromatic ring containing 1 or 2 nitrogen heteroatoms.
[0032] 1.8. Compounds according to Embodiment 1.6 or Embodiment 1.7, wherein R 1 is an optionally substituted 5- or 6-membered aromatic ring containing 1 or 2 nitrogen heteroatoms, wherein the optional substituents are selected from C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, oxo, hydroxyl or amino.
[0033] 1.9. A compound according to any one of Embodiments 1.1 to 1.8, wherein R 5 Selected from COR 7 , optionally substituted with a 6-membered aromatic ring containing 0, 1 or 2 nitrogen heteroatoms 1-6 A hydrocarbon group; or R 5 Can be used with R 6 are joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms, or R 7 Can be used with R 6 Joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms.
[0034] 1.10. Compounds according to Embodiment 1.9, wherein R5 COCH3, non-aromatic C 1-6 A hydrocarbon group, or R 5 Can be used with R 6 are joined together to form an optionally substituted monocyclic ring, or R 5 It is COR 7 , where R 7 Can be used with R 6 Joined together to form an optionally substituted single ring.
[0035] 1.11. Compounds according to Embodiment 1.10, wherein R 5 COCH3, non-aromatic C 1-6 A hydrocarbon group; or R 5 Can be used with R 6 are joined together to form an optionally substituted monocyclic ring, wherein the optional substituent is selected from C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, oxo, hydroxyl or amino, wherein the C1-C3 alkyl group or the C1-C3 alkoxy group may have an optional substituent selected from halogen, cyano, oxo, hydroxyl or amino; or R 5 It is COR 7 , where R 7 Can be used with R 6 are joined together to form an optionally substituted monocyclic ring, wherein the optional substituent is selected from C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, oxo, hydroxyl or amino, wherein the C1-C3 alkyl group or the C1-C3 alkoxy group may have an optional substituent selected from halogen, cyano, oxo, hydroxyl or amino.
[0036] 1.12. A compound according to any one of Embodiments 1.1 to 1.11, wherein R 6 is selected from hydrogen, a non-aromatic C optionally substituted by a 6-membered optionally substituted aromatic ring containing 0, 1 or 2 nitrogen heteroatoms 1-6 A hydrocarbon group, or R 6 Can be used with R 5 or R 7 Joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and their oxidized forms.
[0037] 1.13. Compounds according to Embodiment 1.12, wherein R 6 is hydrogen, a non-aromatic C optionally substituted by an optionally substituted phenyl ring 1-6 A hydrocarbon group, or R 6 Can be used with R 5 or R 7 Joined together to form an optionally substituted single ring.
[0038] 1.14. Compounds according to Embodiment 1.13, wherein R 6 is hydrogen, a non-aromatic C optionally substituted by an optionally substituted phenyl ring 1-6 A hydrocarbon group, wherein the optional substituents on the phenyl ring are selected from C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, oxo, hydroxyl or amino, wherein the C1-C3 alkyl group or C1-C3 alkoxy group may have an optional substituent selected from halogen, cyano, oxo, hydroxyl or amino; or R 6 Can be used with R 5 or R 7 are joined together to form an optionally substituted monocyclic ring, wherein the optional substituent is selected from C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, oxo, hydroxyl or amino, wherein the C1-C3 alkyl group or the C1-C3 alkoxy group may have an optional substituent selected from halogen, cyano, oxo, hydroxyl or amino.
[0039] 1.15. Compounds according to Embodiment 1.3, wherein R 8 It is hydrogen, non-aromatic C 1-6 A hydrocarbon group, or R 8 Can be used with R 9 Joined together to form an optionally substituted monocyclic ring, wherein the optional substituent is selected from C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, oxo, hydroxyl or amino.
[0040] 1.16. Compounds according to Embodiment 1.3, wherein R 9 Non-aromatic C 1-6 A hydrocarbon group, or R 9 Can be used with R 8 Joined together to form an optionally substituted monocyclic ring, wherein the optional substituent is selected from C1-C3 alkyl, C1-C3 alkoxy, halogen, cyano, oxo, hydroxyl or amino.
[0041] 1.17. A compound according to any one of Embodiments 1.1 to 1.16, which is a compound of formula (1):
[0042]
[0043] or a salt thereof, wherein:
[0044] R 1 R 2 Selected from:
[0045]
[0046]
[0047] 1.18. A compound according to any one of Embodiments 1.1 to 1.17, wherein R 4 is H or an acyclic C optionally substituted by one or more fluorine atoms 1-4 Hydrocarbon group.
[0048] 1.19. Compounds according to Embodiment 1.18, wherein R 4 is H or an acyclic C optionally substituted by one or more fluorine atoms 1-3 Hydrocarbon group.
[0049] 1.20. Compounds according to Embodiment 1.19, wherein R 4 Is H or C 1-3 Alkyl group or C 1-2 Alkynyl group.
[0050] 1.21 A compound according to Embodiment 1.20 wherein R 4 is selected from H, methyl, fluoromethyl, ethyl, ethynyl and 1-propynyl.
[0051] 1.22 A compound according to Embodiment 1.21 wherein R 4 It's methyl.
[0052] 1.23 A compound according to Embodiment 1.21 wherein R 4 It's H.
[0053] 1.24 A compound according to Embodiment 1.1, which is defined as in any one of Embodiments 1-1 to 8-25.
[0054] 1.25 A compound according to any one of Embodiments 1.1 to 1.24 having a molecular weight of less than 550, for example less than 500 or less than 450.
[0055] 1.26 A compound according to any one of Embodiments 1.1 to 1.25 which is in the form of a salt.
[0056] 1.27 A compound according to Embodiment 1.26 wherein the salt is an acid addition salt.
[0057] 1.28 A compound according to Embodiment 1.26 or Embodiment 1.27 wherein the salt is a pharmaceutically acceptable salt.
[0058] definition
[0059] In this application, the following definitions apply unless indicated otherwise.
[0060] With respect to the use of compounds of formula (1), the term "treatment" is used to describe any form of intervention in which the compound is administered to a subject suffering from, or at risk of, or potentially at risk of the disease or disorder in question. Thus, the term "treatment" encompasses both preventative (prophylactic) treatment and treatment where measurable or detectable symptoms of a disease or disorder are being exhibited.
[0061] As used herein, the term "therapeutically effective amount" (e.g., with respect to a treatment method for a disease or condition) refers to an amount of a compound that is effective to produce the desired therapeutic effect. For example, if the condition is pain, the therapeutically effective amount is an amount sufficient to provide a desired level of pain relief. The desired level of pain relief can be, for example, complete elimination of pain or a reduction in the severity of pain.
[0062] The term "non-aromatic hydrocarbon group" (as in "C 1-5 Non-aromatic hydrocarbon groups" or "acyclic C 1-5 A "non-aromatic hydrocarbon group" refers to a group consisting of carbon atoms and hydrogen atoms and not containing an aromatic ring. The hydrocarbon group may be fully saturated or may contain one or more carbon-carbon double bonds or carbon-carbon triple bonds or a mixture of double bonds and triple bonds. The hydrocarbon group may be a straight chain or branched chain group or may consist of or contain a cyclic group. Thus, the term non-aromatic hydrocarbon includes alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, and the like.
[0063] Unless otherwise indicated, the terms "alkyl," "alkenyl," "alkynyl," "cycloalkyl," and "cycloalkenyl" are used in their conventional sense (eg, as defined in the IUPAC Gold Book).
[0064] As used herein, term "cycloalkyl" (wherein a specified number of carbon atoms is allowed) includes monocyclic cycloalkyl groups such as cyclopropyl groups, cyclobutyl groups, cyclopentyl groups, cyclohexyl groups and cycloheptyl groups, as well as bicyclic groups and tricyclic groups. Bicyclic cycloalkyl groups include bridged ring systems, such as bicycloheptane, bicyclooctane and adamantane.
[0065] In the above R 1 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9In the definition of, where stated, one or two but not all carbon atoms of the non-aromatic hydrocarbon group may optionally be replaced by heteroatoms selected from O, N and S and their oxidized forms. It will be understood that when a carbon atom is replaced by a heteroatom, the lower valence of the heteroatom compared to carbon means that fewer atoms will be bonded to the heteroatom than to the carbon atom that has been replaced. Thus, for example, replacing a carbon atom (valence 4) in a CH2 group by oxygen (valence 2) will mean that the resulting molecule will contain two fewer hydrogen atoms, and replacing a carbon atom (valence 4) in a CH2 group by nitrogen (valence 3) will mean that the resulting molecule will contain one less hydrogen atom.
[0066] Examples of heteroatom replacements for carbon atoms include replacement of carbon atoms in a -CH2-CH2-CH2- chain with oxygen or sulfur to give an ether -CH2-O-CH2- or a thioether -CH2-S-CH2-, replacement of a carbon atom in a group CH2-C≡CH with nitrogen to give a nitrile (cyano) group CH2-C≡N, replacement of a carbon atom in a group -CH2-CH2-CH2- with C=O to give a ketone -CH2-C(O)-CH2-, replacement of a carbon atom in a group -CH2-CH2-CH2- with S=O or SO2 ... S=O or SO2 to give a ketone -CH2-C(O)-CH2-, replacement of a carbon atom in a group -CH2-CH2-CH2- with S=O or SO2 to give a ketone -CH2-C(O)-CH2-, replacement of a carbon atom in a group -CH2-CH2-CH2- with S=O or SO2 to give a ketone -CH2-C(O)-CH2-, replacement of a carbon atom in a group - To give a sulfoxide -CH2-S(O)-CH2- or a sulfone -CH2-S(O)2-CH2-, to replace a carbon atom in a -CH2-CH2-CH2- chain with C(O)NH to give an amide -CH2-CH2-C(O)-NH-, to replace a carbon atom in a -CH2-CH2-CH2- chain with nitrogen to give an amine -CH2-NH-CH2-, and to replace a carbon atom in a -CH2-CH2-CH2- chain with C(O)O to give an ester (or carboxylic acid) -CH2-CH2-C(O)-O-. In each such substitution, at least one carbon atom in the hydrocarbon group must be retained.
[0067] Salt
[0068] Many compounds of formula (1) may exist in the form of salts, for example acid addition salts or, in certain cases, salts of organic and inorganic bases such as carboxylates, sulfonates and phosphates. All such salts are within the scope of the invention and references to compounds of formula (1) include salt forms of compounds as defined in Embodiments 1.26 to 1.28.
[0069] The salts are typically acid addition salts.
[0070] The salts of the present invention can be synthesized from a parent compound containing a basic or acidic moiety by conventional chemical methods such as those described in Pharmaceutical Salts: Properties, Selection, and Use, P. Heinrich Stahl (ed.), Camille G. Wermuth (ed.), ISBN: 3-90639-026-8, Hardcover, p. 388, August 2002. Typically, such salts can be prepared by reacting the free acid or free base forms of these compounds with an appropriate base or acid in water or an organic solvent or a mixture of the two; typically using a non-aqueous medium such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile.
[0071] Acid addition salts (as defined in Embodiment 1.27) can be formed with a wide variety of acids, both inorganic and organic. Examples of acid addition salts falling within Embodiment 1.27 include mono- or di-salts formed with an acid selected from the group consisting of acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid (e.g., L-ascorbic acid), L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, butyric acid, (+) camphoric acid, camphor-sulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, mucic acid, gentisic acid, glucoheptonic acid, D-gluconic acid, glucuronic acid (e.g., D-glucuronic acid), glutamic acid (e.g., L-glutamic acid), α-ketoglutaric acid (α-oxoglutaric acid), acid), glycolic acid, hippuric acid, hydrohalic acids (e.g., hydrobromic acid, hydrochloric acid, hydroiodic acid), isethionic acid, lactic acid (e.g., (+)-L-lactic acid, (±)-DL-lactic acid), lactobionic acid, maleic acid, malic acid, (-)-L-malic acid, malonic acid, (±)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, pyruvic acid, L-pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, undecylenic acid, and valeric acid, as well as acylated amino acids and cation exchange resins.
[0072] In case the compounds of formula (1) contain amine functional groups, these can form quaternary ammonium salts (embodiment 1.29), for example by reaction with alkylating agents according to methods well known to the skilled person. Such quaternary ammonium compounds are within the scope of formula (1).
[0073] The compounds of the present invention may exist as mono- or di-salts depending on the pKa of the acid forming the salt.
[0074] The salt forms of the compounds of the present invention are generally pharmaceutically acceptable salts, and examples of pharmaceutically acceptable salts are discussed in Berge et al., 1977, "Pharmaceutically Acceptable Salts," J. Pharm. Sci., Vol. 66, pp. 1-19. However, non-pharmaceutically acceptable salts may also be prepared as intermediate forms, which may then be converted into pharmaceutically acceptable salts. Such non-pharmaceutically acceptable salt forms, which may be useful, for example, in the purification or isolation of the compounds of the present invention, also form part of the present invention.
[0075] Stereoisomers
[0076] Stereoisomers are isomeric molecules that have the same molecular formula and sequence of bonded atoms but differ only in the three-dimensional orientation of their atoms in space. Stereoisomers may be, for example, geometric isomers or optical isomers.
[0077] Geometric isomers
[0078] In the case of geometric isomers, the isomerism is due to different orientations of atoms or groups about a double bond, such as cis and trans (Z and E) isomerism around a carbon-carbon double bond, or cis and trans isomerism around an amide bond, or cis and trans isomerism around a carbon-nitrogen double bond (for example in oximes), or rotational isomerism around a bond about which there is restricted rotation, or cis and trans isomerism around a ring such as a cycloalkane ring.
[0079] Thus, in another embodiment (Embodiment 1.30), the invention provides a geometric isomer of a compound according to any one of Embodiments 1.1 to 1.29.
[0080] Optical isomers
[0081] Where compounds of the formula contain one or more chiral centers and can exist in two or more optical isomeric forms, reference to the compound includes all optical isomeric forms thereof (e.g., enantiomers, epimers and diastereomers), either as individual optical isomers or as mixtures (e.g., racemic mixtures) or two or more optical isomers, unless the context requires otherwise.
[0082] Thus, in another embodiment (Embodiment 1.31), the invention provides a compound according to any one of Embodiments 1.1 to 1.30 comprising a chiral center.
[0083] Optical isomers can be characterized and identified by their optical activity (i.e., as + and - isomers, or d and l isomers) or they can be characterized by their absolute stereochemistry using the "R and S" nomenclature developed by Cahn, Ingold and Prelog, see Jerry March, Advanced Organic Chemistry, 4th edition, John Wiley & Sons, New York, 1992, pages 109-114, and also see Cahn, Ingold & Prelog, Angew. Chem. Int. Ed. Engl., 1966, 5, 385-415. Optical isomers can be separated by a number of techniques including chiral chromatography (chromatography on a chiral support), and such techniques are well known to those skilled in the art. As an alternative to chiral chromatography, optical isomers can be separated by forming diastereomeric salts with chiral acids such as (+)-tartaric acid, (-)-pyroglutamic acid, (-)-di-toluoyl-L-tartaric acid, (+)-mandelic acid, (-)-malic acid and (-)-camphorsulfonic acid, separating the diastereomers by preferential crystallization and then dissociating the salts to give the individual enantiomers of the free base.
[0084] Where the compounds of the invention exist as two or more optical isomeric forms, one enantiomer of a pair of enantiomers may, for example, exhibit an advantage over the other enantiomer in terms of biological activity. Thus, in certain circumstances, it may be desirable to use only one of a pair of enantiomers or only one of more than one diastereomer as a therapeutic agent.
[0085] Thus, in another embodiment (Embodiment 1.32), the invention provides a composition comprising a compound according to Embodiment 1.31 having one or more chiral centers, wherein at least 55% (e.g., at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%) of the compound of Embodiment 1.31 exists as a single optical isomer (e.g., enantiomer or diastereomer).
[0086] In one general embodiment (Embodiment 1.33), 99% or more (e.g. substantially all) of the total amount of the compounds of Embodiment 1.31 (or the compounds for use of Embodiment 1.31) is present as a single optical isomer.
[0087] For example, in one embodiment (Embodiment 1.34), the compound exists as a single enantiomer.
[0088] In another embodiment (Embodiment 1.35), the compound exists as a single diastereomer.
[0089] The present invention also provides a mixture of optical isomers which may be racemic or non-racemic. Therefore, the present invention provides:
[0090] 1.36 A compound according to Embodiment 1.31 which is in the form of a racemic mixture of optical isomers.
[0091] 1.37 A compound according to Embodiment 1.31 which is in the form of a non-racemic mixture of optical isomers.
[0092] isotope
[0093] The compounds of the invention as defined in any one of Embodiments 1.1 to 1.37 may contain one or more isotopic substitutions, and references to a particular element include within its scope all isotopes of that element. For example, references to hydrogen include 1 H. 2 H(D) and 3 H(T) is included within its scope. Similarly, references to carbon and oxygen will be 12 C. 13 C and 14 C and 16 O and 18 O is included in their scope.
[0094] In a similar manner, reference to a particular functional group also includes isotopic variations within its scope unless the context indicates otherwise. For example, reference to an alkyl group such as an ethyl group also encompasses variations in which one or more hydrogen atoms in the group are in the form of deuterium or tritium isotopes, for example, as in an ethyl group in which all five hydrogen atoms are in the form of deuterium isotopes (perdeuterated ethyl group).
[0095] Isotopes may be radioactive or non-radioactive. In one embodiment of the invention (Embodiment 1.38), the compound described in any one of Embodiments 1.1 to 1.37 does not contain a radioactive isotope. Such compounds are preferably used for therapeutic purposes. However, in another embodiment (Embodiment 1.39), the compound described in any one of Embodiments 1.1 to 1.37 may contain one or more radioactive isotopes. Compounds containing such radioactive isotopes may be useful in a diagnostic context.
[0096] Solvate
[0097] Compounds of formula (1) as defined in any one of Embodiments 1.1 to 1.39 may form solvates. Preferred solvates are solvates formed by incorporating molecules of a non-toxic pharmaceutically acceptable solvent (hereinafter referred to as a solvating solvent) into the solid state structure (e.g., crystal structure) of the compound of the present invention. Examples of such solvents include water, alcohols (such as ethanol, isopropanol and butanol) and dimethyl sulfoxide. Solvates may be prepared by recrystallizing the compound of the present invention with a solvent or a solvent mixture containing a solvating solvent. Whether a solvate has been formed in any given case may be determined by subjecting the crystals of the compound to analysis using well-known and standard techniques such as thermogravimetric analysis (TGE), differential scanning calorimetry (DSC) and X-ray crystallography. Solvates may be stoichiometric or non-stoichiometric solvates. Particularly preferred solvates are hydrates, and examples of hydrates include hemihydrates, monohydrates and dihydrates.
[0098] Thus, in further embodiments 1.40 and 1.41, the invention provides:
[0099] 1.40 A compound according to any one of Embodiments 1.1 to 1.39 in the form of a solvate.
[0100] 1.41 A compound according to Embodiment 1.40 wherein the solvate is a hydrate.
[0101] For a more detailed discussion of solvates and methods for preparing and characterizing them, see Bryn et al., Solid-State Chemistry of Drugs, 2nd edition, published by SSCI, Inc of West Lafayette, IN, USA, 1999, ISBN 0-967-06710-3.
[0102] Alternatively, the compounds of the invention may be anhydrous rather than existing as hydrates. Thus, in another embodiment (Embodiment 1.42), the invention provides a compound as defined in any one of Embodiments 1.1 to 1.40 in an anhydrous form (eg an anhydrous crystalline form).
[0103] Crystalline and amorphous forms
[0104] The compounds described in any of Embodiments 1.1 to 1.40 may exist in a crystalline or non-crystalline (e.g., amorphous) state. Whether a compound exists in a crystalline state can be easily determined by standard techniques such as X-ray powder diffraction (XRPD). Crystals and their crystal structures can be characterized using a number of techniques, including single crystal X-ray crystallography, X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), and infrared spectroscopy such as Fourier transform infrared spectroscopy (FTIR). The behavior of crystals under different humidity conditions can be studied by weight vapor sorption and also analyzed by XRPD. The determination of the crystal structure of the compound can be carried out by X-ray crystallography which can be carried out according to conventional methods, such as those described herein and as described in Fundamentals of Crystallography, C. Giacovazzo, HL Monaco, D. Viterbo, F. Scordari, G. Gilli, G. Zanotti and M. Catti, (International Union of Crystallography / Oxford University Press, 1992 ISBN 0-19-855578-4 (p / b), 0-19-85579-2 (h / b)). This technique involves the analysis and interpretation of X-ray diffraction of single crystals. In amorphous solids, there is no three-dimensional structure that is usually present in crystalline form, and the positions of the molecules relative to each other in the amorphous form are essentially random, see, for example, Hancock et al. J. Pharm. Sci. (1997), 86, 1).
[0105] Therefore, in further embodiments, the present invention provides:
[0106] 1.43 A compound according to any one of Embodiments 1.1 to 1.42 in crystalline form.
[0107] 1.44 A compound according to any one of Embodiments 1.1 to 1.42 which is:
[0108] (a) from 50% to 100% crystalline, and more particularly at least 50% crystalline, or at least 60% crystalline, or at least 70% crystalline, or at least 80% crystalline, or at least 90% crystalline, or at least 95% crystalline, or at least 98% crystalline, or at least 99% crystalline, or at least 99.5% crystalline, or at least 99.9% crystalline, for example 100% crystalline.
[0109] 1.45 A compound according to any one of Embodiments 1.1 to 1.42 which is in amorphous form.
[0110] Prodrug
[0111] The compounds of formula (1) as defined in any one of Embodiments 1.1 to 1.45 may be presented in the form of a prodrug. "Prodrug" means any compound which is converted in vivo, for example, to a biologically active compound of formula (1) as defined in any one of Embodiments 1.1 to 1.45.
[0112] For example, some prodrugs are esters of active compounds (e.g., physiologically acceptable metabolically labile esters). During metabolism, the ester group (-C(=O)OR) is cleaved to produce the active drug. Such esters can be formed, for example, by esterification of any hydroxyl groups present in the parent compound, where appropriate, any other reactive groups present in the parent compound are pre-protected and subsequently deprotected as desired.
[0113] In addition, some prodrugs are enzymatically activated to produce the active compound, or the compound produces the active compound after further chemical reaction (e.g., as in ADEPT, GDEPT, LIDEPT, etc.). For example, the prodrug may be a sugar derivative or other glycoside conjugate, or may be an ester derivative of an amino acid.
[0114] Thus, in another embodiment (Embodiment 1.46), the invention provides a prodrug of a compound as defined in any one of Embodiments 1.1 to 1.45, wherein the compound contains a functional group which is convertible under physiological conditions to form a hydroxyl group or an amino group.
[0115] Complexes and inclusion compounds
[0116] Formula (1) in Embodiments 1.1 to 1.46 also encompasses complexes of the compounds of Embodiments 1.1 to 1.46 (eg, inclusion complexes or clathrates with compounds such as cyclodextrins, or complexes with metals).
[0117] Thus, in another embodiment (Embodiment 1.47), the invention provides a compound according to any one of Embodiments 1.1 to 1.46 in the form of a complex or inclusion compound.
[0118] Biological activity and therapeutic uses
[0119] The compounds of the invention have activity as muscarinic M1 and / or M4 receptor agonists.The muscarinic activity of the compounds can be determined using the phospho-ERK1 / 2 assay described in Example A below.
[0120] A significant advantage of the compounds of the present invention is that they are highly selective for M1 and / or M4 receptors relative to M2 and M3 receptor subtypes. The compounds of the present invention are neither agonists nor antagonists of M2 and M3 receptor subtypes. For example, given that the compounds of the present invention generally have a pEC of at least 6 (preferably at least 6.5) for M1 and / or M4 receptors in the functional assay described in Example A, 50 value and an E greater than 80 (preferably greater than 95) max Values, when tested against M2 and M3 subtypes in the functional assay of Example A, the compounds of the invention may have a pEC value of less than 5 50 value and less than 20% of E max value.
[0121] Some compounds of the invention are active at both the M1 receptor and the M4 receptor, and some are active at the M4 receptor.
[0122] Thus, in embodiments 2.1 to 2.16, the present invention provides:
[0123] 2.1 A compound according to any one of Embodiments 1.1 to 1.47 for use in medicine.
[0124] 2.2 A compound according to any one of Embodiments 1.1 to 1.47 for use as a muscarinic M1 and / or M4 receptor agonist.
[0125] 2.3 A compound according to any one of Embodiments 1.1 to 1.47, which has a pEC of greater than 6.9 for the M1 receptor in an assay of Example A herein or an assay substantially similar thereto. 50 and an E of at least 80 max A muscarinic M1 receptor agonist.
[0126] 2.4 A compound according to Embodiment 2.3, which has a pEC greater than 7.0 50 A muscarinic M1 receptor agonist.
[0127] 2.5 A compound according to Embodiment 2.3 or Embodiment 2.4 having an E of at least 90 for the M1 receptor max .
[0128] 2.6 A compound according to any one of Embodiments 1.1 to 1.47, which has a pEC in the range of from 6.0 to 7.8 for muscarinic M1 and M4 receptors in an assay of Example A herein, or an assay substantially similar thereto. 50 and an E of at least 70 max Agonist of muscarinic M1 and M4 receptors.
[0129] 2.7 A compound according to any one of Embodiments 1.1 to 1.47, which has a pEC greater than 7.0 50 A muscarinic M4 receptor agonist.
[0130] 2.8 A compound according to Embodiment 2.6 or Embodiment 2.7 having an E of at least 90 for the M4 receptor max .
[0131] 2.9 A compound according to any one of Embodiments 1.1 to 1.47, which has a pEC in the range of from 6.0 to 7.8 for the muscarinic M4 receptor in an assay of Example A herein or an assay substantially similar thereto. 50 and an E of at least 70 max A muscarinic M4 receptor agonist.
[0132] 2.10 A compound according to any one of Embodiments 2.3 to 2.9 which is selective for M1 and M4 receptors compared to muscarinic M2 and M3 receptors.
[0133] 2.11 A compound according to Embodiment 2.9 which is selective for the M4 receptor compared to the muscarinic M2 and M3 receptors.
[0134] 2.12 A compound according to any one of Embodiments 2.3 to 2.5 which is selective for the Ml receptor over the muscarinic M2, M3 and M4 receptors.
[0135] 2.13 A compound according to Embodiment 2.7 or 2.9 which is selective for the M4 receptor compared to the muscarinic M1, M2 and M3 receptors.
[0136] 2.14 A compound according to any one of Embodiments 2.3 to 2.13, which has a pEC of less than 5 for muscarinic M2 and M3 receptor subtypes. 50 and E less than 50 max .
[0137] 2.15 A compound according to Embodiment 2.14 having a pEC of less than 4.5 for muscarinic M2 and M3 receptor subtypes 50 and / or E less than 30 max .
[0138] 2.16 A compound according to any one of Embodiments 1.1 to 1.47 and Embodiments 2.3 to 2.15 for use in treating a disease or condition mediated by muscarinic M1 and / or M4 receptors.
[0139] Due to their muscarinic M1 and / or M4 receptor agonist activity, the compounds of the present invention can be used to treat Alzheimer's disease, schizophrenia and other psychotic disorders, cognitive disorders and other diseases mediated by muscarinic M1 and / or M4 receptors, and can also be used to treat various types of pain.
[0140] Thus, in Embodiments 2.17 to 2.38, the present invention provides:
[0141] 2.17 A compound according to any one of Embodiments 1.1 to 1.47 for use in treating a cognitive disorder or a psychotic disorder.
[0142] 2.18 A compound for use according to Embodiment 2.17 wherein the cognitive disorder or psychotic disorder comprises or is caused by or is associated with a condition selected from the group consisting of cognitive impairment, mild cognitive impairment (including mild cognitive impairment due to Alzheimer's disease and / or prodromal Alzheimer's disease), frontotemporal dementia, vascular dementia, dementia with Lewy bodies, presenile dementia, senile dementia, Friederich's ataxia, Down syndrome, Huntington's disease, hyperkinesia, mania, Tourette syndrome, Alzheimer's disease (including those described in the "Early Alzheimer's disease: Developing Drugs for Treatment” as defined in the “Dementia Treatment”, prodromal Alzheimer’s disease and early Alzheimer’s disease stages 1, 2, and 3), progressive supranuclear palsy, impairment of cognitive function including attention, orientation, learning impairment, memory (i.e., memory impairment, amnesia, amnesic disorder, transient global amnesia syndrome, and age-related memory impairment), and language function; cognitive impairment due to stroke, Huntington’s disease, Pick’s disease, AIDS-related dementia or other dementing states such as multi-infarct dementia, alcoholic dementia, dementia associated with hypothyroidism, and dementia associated with other degenerative disorders such as cerebellar atrophy and amyotrophic lateral sclerosis; other acute or subacute conditions that can lead to cognitive impairment such as delirium or depression (pseudo-dementia state) trauma, head trauma, age-related cognitive impairment, stroke, neurodegeneration, drug-induced states, neurotoxic agents, age-related cognitive impairment, cognitive impairment associated with autism, Down syndrome, Cognitive deficits associated with psychosis, and cognitive impairment associated with electroconvulsive therapy; cognitive impairment due to drug abuse or withdrawal including nicotine, marijuana, amphetamines, cocaine, attention deficit hyperactivity disorder (ADHD) and movement disorders such as Parkinson's disease, neuroleptic-induced Parkinson's disease and tardive dyskinesia, schizophrenia, schizophreniform disorders, psychotic depression, mania, acute mania, paranoid, hallucinogenic and delusional disorders, personality disorders, obsessive-compulsive disorder, schizotypal disorder, delusional disorder, psychosis due to malignancy, metabolic disorders, endocrine diseases or hypersomnia, psychosis due to drug abuse or withdrawal, bipolar disorder, and schizoaffective disorder.
[0143] 2.19 A compound according to any one of Embodiments 1.1 to 1.47 for use in treating Alzheimer's disease or dementia with Lewy bodies.
[0144] 2.20 A compound according to any one of Embodiments 1.1 to 1.47 for use in treating schizophrenia.
[0145] 2.21 A method of treating a cognitive disorder in a subject (eg, a mammalian patient such as a human, eg, a human in need of such treatment), the method comprising administering a therapeutically effective dose of a compound according to any one of Embodiments 1.1 to 1.47.
[0146] 2.22 A method according to Embodiment 2.21 wherein the cognitive impairment comprises, is caused by or is associated with a condition as defined in Embodiment 2.18.
[0147] 2.23 A method according to Embodiment 2.22 wherein the cognitive impairment is caused by or is associated with Alzheimer's disease or dementia with Lewy bodies.
[0148] 2.24 A method according to Embodiment 2.22 wherein the cognitive disorder is schizophrenia.
[0149] 2.25 Use of a compound according to any one of Embodiments 1.1 to 1.47 for the manufacture of a medicament for the treatment of a cognitive disorder.
[0150] 2.26 The use according to Embodiment 2.25 wherein the cognitive impairment comprises, is caused by or is associated with a condition as defined in Embodiment 2.18.
[0151] 2.27 The use according to Embodiment 2.26 wherein the cognitive impairment is caused by or associated with Alzheimer's disease or dementia with Lewy bodies.
[0152] 2.28 The use according to Embodiment 2.26 wherein the cognitive disorder is schizophrenia.
[0153] 2.29 A compound according to any one of Embodiments 1.1 to 1.47 for use in treating or lessening the severity of acute, chronic, neuropathic or inflammatory pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpetic neuralgia, general neuralgia, visceral pain, osteoarthritis pain, post-herpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postoperative pain or cancer pain.
[0154] 2.30 A method of treating or lessening the severity of acute, chronic, neuropathic or inflammatory pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpetic neuralgia, general neuralgia, visceral pain, osteoarthritis pain, post-herpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postoperative pain or cancer pain, comprising administering a therapeutically effective dose of a compound according to any one of Embodiments 1.1 to 1.47.
[0155] 2.31 A compound according to any one of Embodiments 1.1 to 1.47 for use in treating a peripheral disorder such as reducing intraocular pressure in glaucoma and treating dry eyes and dry mouth including Sjögren's syndrome.
[0156] 2.32 A method of treating a peripheral disorder such as reducing intraocular pressure in glaucoma and treating dry eyes and dry mouth, including Sjögren's syndrome, comprising administering a therapeutically effective dose of a compound according to any one of Embodiments 1.1 to 1.47.
[0157] 2.33 Use of a compound according to any one of Embodiments 1.1 to 1.47 for the manufacture of a medicament for treating or lessening the severity of acute, chronic, neuropathic or inflammatory pain, arthritis, migraine, cluster headache, trigeminal neuralgia, herpetic neuralgia, general neuralgia, visceral pain, osteoarthritis pain, post-herpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, post-operative pain or cancer pain, or for the manufacture of a medicament for treating peripheral disorders such as reducing intraocular pressure in glaucoma and treating dry eyes and dry mouth, including Sjögren's syndrome.
[0158] 2.34 Use of a compound according to any one of Embodiments 1.1 to 1.47 for treating skin lesions, for example due to pemphigus vulgaris, dermatitis herpetiformis, pemphigoid and other blistering skin conditions.
[0159] 2.35 Use of a compound according to any one of Embodiments 1.1 to 1.47 for treating, preventing, ameliorating or reversing conditions associated with altered gastrointestinal function and motility, such as symptoms of functional dyspepsia, irritable bowel syndrome, gastroesophageal acid reflux (GER) and esophageal dysmotility, gastroparesis and chronic diarrhea.
[0160] 2.36 Use of a compound according to any one of Embodiments 1.1 to 1.47 for treating olfactory dysfunction such as Bosma-Henkin-Christiansen syndrome, chemical poisoning (eg, selenium and silver), hypopituitarism, Kallmann syndrome, skull fractures, tumor therapy and underactive thyroid.
[0161] 2.37 Use of a compound according to any one of Embodiments 1.1 to 1.47 for treating addiction.
[0162] 2.38 Use of a compound according to any one of Embodiments 1.1 to 1.47 for treating movement disorders such as Parkinson's disease, ADHD, Huntington's disease, Tourette's syndrome and other syndromes associated with dopaminergic dysfunction as an underlying pathogenic factor driving the disease.
[0163] 2.39 Use of a compound according to any one of Embodiments 1.1 to 1.47 for treating behavioral and psychological symptoms of dementia (BPSD; including agitation, verbal aggression, physical aggression, depression, anxiety, abnormal motor behavior, elevated mood, dysphoria, apathy, disinhibition, impulsivity, delusions, hallucinations, sleep changes and appetite changes).
[0164] Method for preparing the compound of formula (1)
[0165] Compounds of formula (1) can be prepared according to synthetic methods well known to the skilled person and as described herein.
[0166] Thus, in another embodiment (Embodiment 3.1), the present invention provides a process for preparing a compound as defined in any one of Embodiments 1.1 to 1.47, the process comprising:
[0167] (A) making a compound of formula (10):
[0168]
[0169] With the compound of formula (11):
[0170]
[0171] Reaction under reductive amination conditions; where R 1 , R 2 and R 4 is defined in accordance with any one of Embodiments 1.1 to 1.47; or
[0172] B) making a compound of formula (12):
[0173]
[0174] With the formula LG-C(=O)-O-CH2-R 4 The compound reaction; where R 1 , R 2 and R 4 is defined according to any one of Embodiments 1.1 to 1.47, and LG represents a suitable leaving group such as C1, 1-imidazole or 4-nitrophenol; or
[0175] (C) When it is necessary to prepare 1 Includes CONR 8 R 9 When the compound of formula (1) is:
[0176] The compound of formula (13):
[0177]
[0178] With formula R 8 R 9 NH amine reaction; wherein R represents a suitable group such as methyl or ethyl, and R 2 , R 4 , R 8 and R 9 is defined in accordance with any one of Embodiments 1.1 to 1.47; or
[0179] (D) When it is necessary to prepare 1 Includes CONR 8 R 9 When the compound of formula (1) is:
[0180] The compound of formula (14):
[0181]
[0182] With formula R 8 R 9 Amine reaction of NH; where R 2 , R 4 , R 8 and R 9 is defined in accordance with any one of Embodiments 1.1 to 1.47;
[0183] and optionally:
[0184] (E) converting a compound of formula (1) into another compound of formula (1).
[0185] In process variant (A), ketone (11) is reacted with amine (10) under reductive amination conditions. The reductive amination reaction is generally carried out at ambient temperature to mild heating (e.g., at a temperature of about 20° C. to about 70° C.) using a borohydride reducing agent such as sodium triacetoxyborohydride (STAB) in a solvent such as dichloromethane (DCM), dichloroethane (DCE), N,N-dimethylformamide (DMF) or methanol (MeOH) containing an acid such as acetic acid (AcOH) or trifluoroacetic acid (TFA), or sodium cyanoborohydride (NaCNBH3) in combination with zinc chloride (ZnCl2) in a solvent such as MeOH, or in combination with titanium tetraisopropoxide (Ti(O)2) in a solvent such as DCM or DCE containing an acid such as AcOH or TFA. i Optionally, the amine (10) may be present in the reaction as an acid salt such as a hydrogen chloride (HCl) salt, a hydrogen bromide (HBr) salt or a TFA salt, optionally in the presence of a tertiary base such as triethylamine (TEA) or N,N-diisopropylamine (DIPEA).
[0186] Amines of formula (10) may be of commercial origin or may be prepared by a variety of methods known in the art and well known to those skilled in the art. 1 includes an optionally substituted 5-membered or 6-membered aromatic ring and R 2 When the compound of formula (1) is hydrogen, the amine of formula (10) can be prepared by the reaction sequence shown in Scheme 1 below:
[0187]
[0188] Thus, compounds of formula (15) wherein R is hydrogen or two R groups are joined together as -C(CH3)2-C(CH3)2- and PG represents a suitable protecting group such as tert-butyloxycarbonyl (BOC), benzyloxycarbonyl (CBZ) or benzyl (Bn) may be reacted with compounds wherein R 1Compounds of formula (16) where LG is an optionally substituted 5- or 6-membered aromatic ring and LG represents a suitable leaving group such as halogen (e.g. iodine, bromine or chloride) or sulfonate (e.g. tosylate, mesylate or triflate) are reacted under suitable palladium-catalyzed 'Suzuki' coupling conditions well known to the skilled person to form compounds of formula (17). For example, suitable palladium-catalyzed coupling conditions may include reaction with a suitable catalyst such as palladium(II) acetate (Pd(OAc)2), tetrakis(triphenylphosphine)palladium(0) (Pd(Ph3)4), tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3), or (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium(II) (Pd(dppf)Cl2) under the following conditions: optionally in the presence of a suitable ligand such as tricyclohexylphosphine (P(Cy)3), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (XPhos), 2-dicyclohexylphosphino-2',6'-diisopropylbiphenyl (RuPhos), or 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos), in the presence of a suitable base such as potassium carbonate (K2CO3), potassium phosphate (K3PO4), potassium tert-butoxide (K2PO4), or potassium tert-butoxide (K2CO3). t In the presence of 1,4-dioxane, 1,4-dioxane, 1,4-dioxane, 1,4-bu), 1,4-dioxane, ... For example, when the protecting group PG is BOC, then suitable conditions to achieve its removal may be reaction with an acid such as HCl in a solvent such as 1,4-dioxane or diethyl ether (Et2O), or reaction with TFA in a solvent such as DCM. Alternatively, when the protecting group PG is CBZ or Bn, then the amine (19) can be directly formed in one step from the compound of formula (17) by using suitable hydrogenation conditions such as reaction with H2 in the presence of Pd / C or palladium hydroxide on carbon (Pd(OH)2 / C) catalyst in a suitable solvent such as EtOH or MeOH at a temperature of about 20°C to about 80°C.
[0189] Alternatively, when it is desired to prepare a 2 is hydrogen and R 1 Including NR 6 COR 7 (where R 6 Non-aromatic C 1-6 The hydrocarbon group and R 7 When is a compound of formula (1) as defined in any one of Embodiments 1.1 to 1.47, the amine of formula (10) may be prepared by the reaction sequence shown in Scheme 2 below:
[0190]
[0191] Thus, a ketone of formula (20) wherein PG represents a suitable protecting group such as BOC, CBZ or Bn may be reacted with a ketone wherein R 6 Non-aromatic C 1-6 The amine of formula (21) containing a hydrocarbon group is reacted under reductive amination conditions to form a compound of formula (22). The reductive amination reaction is generally carried out at ambient temperature to mild heating (e.g., at a temperature of about 20° C. to about 70° C.) using a borohydride reducing agent such as STAB in a solvent such as DCM, DCE, DMF or MeOH containing an acid such as AcOH or TFA, or NaCNBH in combination with ZnCl in a solvent such as MeOH, or with Ti(O i Optionally, the amine of formula (21) may be present in the reaction as an acid salt such as HCl salt, HBr salt or TFA salt, optionally in the presence of a tertiary base such as TEA or DIPEA. Alternatively, when the protecting group PG is unstable under hydrogenation conditions, the reductive amination reaction may be accomplished by using H2 in the presence of Pd / C or Pd(OH)2 / C catalyst in a suitable solvent such as EtOH or MeOH at a temperature of about 20°C to about 80°C. After formation, the compound of formula (22) may be reacted with a compound wherein R 7A compound of formula (23) or a compound of formula (24) as defined in any one of Embodiments 1.1 to 1.47 and wherein LG represents an OH group or a suitable leaving group such as C1, 1-imidazole or RO(C=O)O (wherein R represents a group such as ethyl or isobutyl) is reacted under acylation conditions to form amide (25). For the reaction between a compound of formula (22) and a compound of formula (23), suitable acylation conditions may be a reaction at a temperature between about 0°C and about 100°C in a solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA. For the reaction between a compound of formula (22) and a compound of formula (24) wherein LG represents an OH group, the skilled person will be familiar with the fact that there are many suitable conditions in the art for achieving the formation of amide (25). For example, with amide coupling reagents such as diisopropylcarbodiimide (DIC), ethyl-(N',N'-dimethylamino)propylcarbodiimide hydrochloride (EDC), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), (1-cyano-2-ethoxy-2-oxoethyleneaminooxy) The acylation conditions may be a reaction between a compound of formula (22) and a compound of formula (24) wherein LG represents a leaving group such as Cl, 1-imidazole or RO(C=O)O (wherein R represents a group such as ethyl or isobutyl) and dimethylamino-morpholinyl-carbonium hexafluorophosphate (COMU) or 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphate-2,4,6-trioxide (T3P), optionally in the presence of a tertiary base such as TEA or DIPEA, optionally in the presence of 1-hydroxybenzotriazole (HOBt), in a solvent such as DCM, THF or DMF, at a temperature between about 0°C and about 100°C. Alternatively, for the reaction between a compound of formula (22) and a compound of formula (24) wherein LG represents a leaving group such as Cl, 1-imidazole or RO(C=O)O (wherein R represents a group such as ethyl or isobutyl), suitable acylation conditions may be a reaction at a temperature between about 0°C and about 100°C in a solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA. After formation, the protecting group PG can be removed from the compound of formula (25) using suitable conditions to form the amine (26). For example, when the protecting group PG is BOC, then suitable conditions to achieve its removal can be reaction with an acid such as hydrogen chloride (HCl) in a solvent such as 1,4-dioxane or Et2O, or reaction with TFA in a solvent such as DCM. Alternatively, when the protecting group PG is CBZ or Bn, then suitable deprotection conditions can be reaction with H2 in the presence of a Pd / C or Pd(OH)2 / C catalyst in a suitable solvent such as EtOH or MeOH at a temperature of about 20°C to about 80°C.
[0192] Alternatively, when it is desired to prepare a1 When the compound of formula (1) is an optionally substituted monocyclic or bicyclic lactam ring of the following form:
[0193]
[0194] Amines of formula (10) can be prepared by the reaction sequence shown in Scheme 3 below:
[0195]
[0196] Therefore, R 2 Amines of formula (27) defined according to any one of Embodiments 1.1 to 1.47 and PG representing a suitable protecting group such as BOC, CBZ or Bn may be reacted with wherein LG 1 and LG 2 Compounds of formula (28) which may be the same or different and represent a suitable leaving group are reacted to form amides of formula (29). For example, LG 1 may represent an OH group, or a group such as C1, 1-imidazole or RO(C=O)O (wherein R represents a group such as ethyl or isobutyl), and LG 2 LG may represent a halogen such as Cl, Br or I, or a sulfonate such as tosylate (OTs), mesylate (OMs) or triflate (OTf). 1 When LG represents an OH group, an amide of formula (29) can be formed from a compound of formula (27) and a compound of formula (28) by using an amide coupling reagent such as DIC, EDC, PyBOP, HATU, COMU or T3P, optionally in the presence of a tertiary base such as TEA or DIPEA, optionally in the presence of HOBt, in a solvent such as DCM, THF or DMF, at a temperature between about 0°C and about 100°C. Alternatively, when LG represents an OH group, an amide of formula (29) can be formed from a compound of formula (27) and a compound of formula (28) by using an amide coupling reagent such as DIC, EDC, PyBOP, HATU, COMU or T3P, optionally in the presence of a tertiary base such as TEA or DIPEA, optionally in the presence of HOBt, in a solvent such as DCM, THF or DMF, at a temperature between about 0°C 1 When R represents a group such as C1, 1-imidazole or RO(C=O)O (wherein R represents a group such as ethyl or isobutyl), the amide of formula (29) can be formed from a compound of formula (27) and a compound of formula (28) by reaction at a temperature between about 0°C and about 100°C in a solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA. After formation, the amide of formula (29) can be cyclized to form a lactam of formula (30). Typical cyclization conditions can be a reaction in a suitable solvent such as THF, DMF or N-methyl-2-pyrrolidone (NMP) at a temperature between about 0°C and about 100°C with a suitable base such as sodium hydride (NaH), K2CO3, Cs2CO3, K tOBu, TEA or DIPEA treatment. After formation, the protecting group PG can be removed from the lactam of formula (30) using suitable conditions to form amine (31). For example, when the protecting group PG is BOC, then suitable conditions for achieving its removal can be reaction with an acid such as HCl in a solvent such as 1,4-dioxane or Et2O, or reaction with TFA in a solvent such as DCM. Alternatively, when the protecting group PG is CBZ or Bn, then suitable deprotection conditions can be reaction with H2 in a suitable solvent such as EtOH or MeOH at a temperature of about 20°C to about 80°C in the presence of a Pd / C or Pd(OH)2 / C catalyst.
[0197] Ketones of formula (11) can be prepared by the reaction sequence shown in Scheme 4 below:
[0198]
[0199] Solution 4
[0200] Thus, a protected aminoketone of formula (32) wherein PG represents a suitable protecting group such as BOC, CBZ or Bn may be deprotected to give the aminoketone (33). For example, when the protecting group PG is BOC, then suitable conditions to effect its removal may be reaction with an acid such as HCl in a solvent such as 1,4-dioxane or Et2O, or reaction with TFA in a solvent such as DCM. Alternatively, when the protecting group PG is CBZ or Bn, then suitable deprotection conditions may be reaction with H2 in the presence of a Pd / C or Pd(OH)2 / C catalyst in a suitable solvent such as EtOH or MeOH at a temperature of about 20°C to about 80°C. After formation, the aminoketone (33) may be reacted with a cyclopentane or a di ... 4 A compound of formula (34) as defined in any one of Embodiments 1.1 to 1.47 and wherein LG represents a suitable leaving group such as C1, 1-imidazole or 4-nitrophenol is reacted under suitable conditions to form ketone (11). Typically, such conditions are a reaction at a temperature between about 0°C and about 50°C in a solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA.
[0201] In process variant (B), an amine of formula (12) is usually reacted with an amine in which R 4 is defined according to any one of Embodiments 1.1 to 1.47 and LG represents a suitable leaving group such as C1, 1-imidazole or 4-nitrophenol of the formula LG-C(=O)-O-CH2-R 4 The compound of is reacted at a temperature between about 0°C to about 50°C in a solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA.
[0202] Amines of formula (12) can be prepared by the reaction sequence shown below in Scheme 5:
[0203]
[0204] Solution 5
[0205] Therefore, R 1 and R 2 Amines of formula (10) as defined in accordance with any one of Embodiments 1.1 to 1.47 may be reacted with ketones (32) wherein PG represents a suitable protecting group such as BOC, CBZ or Bn under reductive amination conditions to form compounds of formula (35). The reductive amination reaction is typically carried out at ambient temperature to mild heating (e.g., at a temperature of about 20° C. to about 70° C.) using a borohydride reducing agent such as STAB in a solvent such as DCM, DCE, DMF or MeOH containing an acid such as AcOH or TFA, or NaCNBH in combination with ZnCl in a solvent such as MeOH, or with Ti(O) in a solvent such as DCM or DCE containing an acid such as AcOH or TFA. i Optionally, the amine of formula (10) may be present in the reaction as an acid salt such as an HCl salt, an HBr salt or a TFA salt, optionally in the presence of a tertiary base such as TEA or DIPEA. Alternatively, when the protecting group PG is unstable under hydrogenation conditions, the reductive amination reaction may be accomplished using H2 in the presence of a Pd / C or Pd(OH)2 / C catalyst in a suitable solvent such as EtOH or MeOH at a temperature of about 20°C to about 80°C. After formation, the protecting group PG may be removed from the compound of formula (35) using suitable conditions to form the amine of formula (12). For example, when the protecting group PG is BOC, then suitable conditions for achieving its removal may be reaction with an acid such as HCl in a solvent such as 1,4-dioxane or Et2O, or reaction with TFA in a solvent such as DCM. Alternatively, when the protecting group PG is CBZ or Bn, then suitable deprotection conditions may be reaction with H2 in the presence of Pd / C or Pd(OH)2 / C catalyst in a suitable solvent such as EtOH or MeOH at a temperature of about 20°C to about 80°C.
[0206] In process variant (C), an ester of formula (13) is reacted with a 8 R 9The amine of NH is reacted under conditions suitable for achieving the formation of an amide. Typically, such conditions are a temperature between about 0°C and about 110°C, in a solvent such as toluene in combination with a reagent such as trimethylaluminum (Me3Al), optionally in the presence of a tertiary base such as TEA or DIPEA. It will be well known to the skilled person that there are many methods for achieving the formation of an ester of formula (13) and a tertiary base of formula R 8 R 9 Other suitable conditions for the formation of amides from NH amines include the reaction in isopropylmagnesium chloride ( i PrMgCl) in a suitable solvent, or by reacting an ester of formula (13) and a compound of formula R in the presence of a suitable solvent and optionally in the presence of a suitable base such as TEA or DIPEA. 8 R 9 The NH amine is directly heated together with the reaction.
[0207] Esters of formula (13) can be prepared by the reaction sequence shown in Scheme 6 below:
[0208]
[0209] Solution 6
[0210] Therefore, R 2 Esters of formula (36) as defined in any one of Embodiments 1.1 to 1.47 and wherein R represents a suitable group such as methyl or ethyl may be reacted with 4 A ketone of formula (11) as defined in any one of Embodiments 1.1 to 1.47 is reacted under reductive amination conditions to form an ester of formula (13). The reductive amination reaction is typically carried out at ambient temperature to mild heating (e.g., at a temperature of about 20° C. to about 70° C.) using a borohydride reducing agent such as STAB in a solvent such as DCM, DCE, DMF or MeOH containing an acid such as AcOH or TFA, or NaCNBH in combination with ZnCl in a solvent such as MeOH, or with Ti(O) in a solvent such as DCM or DCE containing an acid such as AcOH or TFA. i Optionally, the amine of formula (10) may be present in the reaction as an acid salt such as an HCl salt, an HBr salt or a TFA salt, optionally in the presence of a tertiary base such as TEA or DIPEA. Alternatively, when appropriate to do so, the reductive amination reaction may be accomplished using H2 in the presence of a Pd / C or Pd(OH)2 / C catalyst in a suitable solvent such as EtOH or MeOH at a temperature of about 20°C to about 80°C.
[0211] In process variant (D), a carboxylic acid of formula (14) is reacted with a carboxylic acid of formula R 8 R 9The amine of NH is reacted under conditions suitable for achieving the formation of an amide. It will be well known to the skilled person that there are many methods in the art for achieving the formation of an amide from a carboxylic acid of formula (14) and a carboxylic acid of formula R 8 R 9 Many suitable conditions exist for the formation of amides from amines of NH. For example, reaction with an amide coupling reagent such as DIC, EDC, PyBOP, HATU, COMU or T3P, optionally in the presence of a tertiary base such as TEA or DIPEA, optionally in the presence of HOBt, in a solvent such as DCM, THF or DMF at a temperature between about 0°C and about 100°C.
[0212] Carboxylic acids of formula (14) can be prepared by the reaction shown in Scheme 7 below:
[0213]
[0214] Solution 7
[0215] Therefore, R 2 and R 4 Esters of formula (13) as defined in any one of Embodiments 1.1 to 1.47 and in which R represents a suitable group such as methyl or ethyl, tert-butyl or benzyl may be reacted under conditions suitable for achieving cleavage of the ester to form a carboxylic acid of formula (14). Typically, when R represents methyl or ethyl, basic conditions may be used, such as reaction with reagents such as lithium hydroxide (LiOH), sodium hydroxide (NaOH) or potassium hydroxide (KOH) at temperatures between about 0°C and about 100°C in a solvent such as THF, MeOH, EtOH, water (HO) or a combination of two or more of the aforementioned solvents. Alternatively, when R represents tert-butyl, acidic conditions may be used, such as reaction with reagents such as TFA in a solvent such as DCM, or reaction with HCl in a solvent such as 1,4-dioxane or EtO. Alternatively, when R represents benzyl, hydrogenolysis conditions may be used, for example reaction with H2 in the presence of a Pd / C or Pd(OH)2 / C catalyst in a suitable solvent such as EtOH or MeOH at a temperature of about 20°C to about 80°C.
[0216] Alternatively, the carboxylic acid of formula (14) may be reacted with a carboxylic acid of formula R 8 R 9 The amine of NH is reacted to achieve amide formation via the reaction sequence shown in Scheme 8 below:
[0217]
[0218] Solution 8
[0219] Thus, a carboxylic acid of formula (14) can be reacted to form a compound of formula (37) wherein R 2, R 4 , R 8 and R 9 is defined according to any one of Embodiments 1.1 to 1.47 and LG represents a suitable leaving group such as Cl, 1-imidazole or RO(C=O)O (wherein R represents a group such as ethyl or isobutyl). Typically, such conditions are reaction with a reagent such as oxalyl chloride or thionyl chloride (LG=Cl), 1,1'-carbonyldiimidazole (CDI) (LG=1-imidazole) or ethyl or isobutyl chloroformate (LG=RO(C=O)O), optionally in the presence of a tertiary base such as TEA or DIPEA, optionally in the presence of a catalyst such as DMF, in a suitable solvent such as DCM, THF or DMF. After formation, the compound of formula (37) is reacted with a compound of formula R 8 R 9 The NH amine is reacted under conditions suitable to effect formation of the amide (38). Typically, such conditions are reaction at temperatures between about 0°C and about 100°C in a solvent such as DCM, THF or DMF, optionally in the presence of a tertiary base such as TEA or DIPEA.
[0220] In process variant (E), one compound of formula (1) can be converted into another compound of formula (1) by methods well known to the skilled person. Examples of synthetic procedures for converting one functional group into another functional group are described in standard texts such as March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7th edition, Michael B. Smith, John Wiley, 2013, (ISBN: 978-0-470-46259-1), Organic Syntheses, online version, www.orgsyn.org, (ISSN 2333-3553) and Fiesers' Reagents for Organic Synthesis, Volumes 1-17, John Wiley, edited by Mary Fieser (ISBN: 0-471-58283-2).
[0221] In many of the reactions described above, it may be necessary to protect one or more groups to prevent reaction at undesirable locations of the molecule. Examples of protecting groups and examples of methods for protecting and deprotecting functional groups can be found in Greene's Protective Groups in Organic Synthesis, Fifth Edition, Editor: Peter GMWuts, John Wiley, 2014, (ISBN: 9781118057483).
[0222] The compounds prepared by the aforementioned methods can be isolated and purified by any of a variety of methods well known to those skilled in the art, and examples of such methods include recrystallization techniques and chromatographic techniques, such as column chromatography (eg flash chromatography), HPLC and SFC.
[0223] Pharmaceutical preparations
[0224] While it is possible for the active compound to be administered alone, it is preferable to present it as a pharmaceutical composition (eg, formulation).
[0225] Thus, in another embodiment of the invention (Embodiment 4.1), there is provided a pharmaceutical composition comprising at least one compound of formula (1) as defined in any one of Embodiments 1.1 to 1.47 together with at least one pharmaceutically acceptable excipient.
[0226] In one embodiment (Embodiment 4.2), the composition is a tablet composition.
[0227] In another embodiment (Embodiment 4.3), the composition is a capsule composition.
[0228] Pharmaceutically acceptable excipients can be selected from, for example, carriers (e.g., solid carriers, liquid carriers, or semisolid carriers), adjuvants, diluents (e.g., solid diluents such as fillers or bulking agents; and liquid diluents such as solvents and cosolvents), granulating agents, binders, glidants, coating agents, release controlling agents (e.g., polymers or waxes that slow or delay release), binding agents, disintegrants, buffers, lubricants, preservatives, antifungal and antibacterial agents, antioxidants, tonicity regulators, thickeners, flavoring agents, sweeteners, pigments, plasticizers, taste-masking agents, stabilizers, or any other excipients conventionally used in pharmaceutical compositions.
[0229] The term "pharmaceutically acceptable" as used herein means compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of subjects (e.g., human subjects) without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio. Each excipient must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.
[0230] Pharmaceutical compositions comprising compounds of formula (1) can be formulated according to known techniques, see, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.
[0231] The pharmaceutical composition may be in any form suitable for oral, parenteral, topical, intranasal, intrabronchial, sublingual, ophthalmic, otic, rectal, intravaginal or transdermal administration.
[0232] Suitable pharmaceutical dosage forms for oral administration include tablets (coated or uncoated), capsules (hard or soft shell), caplets, pills, lozenges, syrups, solutions, powders, granules, elixirs and suspensions, sublingual tablets, wafers, or patches such as a buccal patch.
[0233] Tablet compositions may contain a unit dose of active compound together with an inert diluent or carrier, such as a sugar or sugar alcohol, e.g., lactose, sucrose, sorbitol, or mannitol; and / or a non-sugar derived diluent, such as sodium carbonate, calcium phosphate, calcium carbonate; or cellulose or its derivatives such as microcrystalline cellulose (MCC), methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, and starch such as corn starch. Tablets may also contain standard ingredients such as: binders and granulating agents, such as polyvinyl pyrrolidone; disintegrants (e.g., swellable cross-linked polymers such as cross-linked carboxymethyl cellulose); lubricants (e.g., stearates); preservatives (e.g., parabens); antioxidants (e.g., BHT); buffers (e.g., phosphate or citrate buffers); and effervescent agents such as citrate / bicarbonate mixtures. Such excipients are well known and need not be discussed in detail herein.
[0234] Tablets may be designed to release the drug upon contact with gastric fluid (immediate release tablets), or to release the drug in a controlled manner over an extended period of time or in a specific area of the GI tract (controlled release tablets).
[0235] The pharmaceutical composition generally comprises from about 1% (w / w) to about 95% (preferably % (w / w)) of active ingredient, and from 99% (w / w) to 5% (w / w) of a pharmaceutically acceptable excipient (e.g., as defined above) or a combination of such excipients. Preferably, the composition comprises from about 20% (w / w) to about 90% (w / w) of active ingredient and from 80% (w / w) to 10% of a pharmaceutically acceptable excipient or a combination of excipients. The pharmaceutical composition comprises from about 1% to about 95%, preferably from about 20% to about 90% of active ingredient. The pharmaceutical composition according to the present invention can, for example, be in the form of a unit dose, such as in the form of an ampoule, a vial, a suppository, a prefilled syringe, a dragee, a powder, a tablet or a capsule.
[0236] Tablets and capsules may contain, for example, 0%-20% disintegrants, 0%-5% lubricants, 0%-5% glidants, and / or 0%-99% (w / w) fillers or expanders (depending on the drug dose). They may also contain 0%-10% (w / w) polymer binders, 0%-5% (w / w) antioxidants, 0%-5% (w / w) pigments. In addition, slow-release tablets will typically contain 0%-99% (w / w) polymers that control (e.g., delay) release (depending on the dose). The film coating of a tablet or capsule typically contains 0%-10% (w / w) polymers, 0%-3% (w / w) pigments, and / or 0%-2% (w / w) plasticizers.
[0237] Parenteral formulations typically contain 0%-20% (w / w) buffer, 0%-50% (w / w) cosolvent and / or 0%-99% (w / w) water for injection (WFI) (depending on the dose and whether lyophilized). Formulations for intramuscular depots may also contain 0%-99% (w / w) oil.
[0238] The pharmaceutical preparations may be provided to the patient in a "patient pack" containing the entire course of treatment in a single package, usually a blister pack.
[0239] The compound of formula (1) will generally be presented in a unit dosage form, and therefore will generally contain enough compound to provide the desired level of biological activity. For example, the formulation may contain from 1 nanogram to 2 grams of active ingredient, for example from 1 nanogram to 2 milligrams of active ingredient. Within these ranges, a specific subrange of the compound is 0.1 milligram to 2 grams of active ingredient (more typically from 10 milligrams to 1 gram, for example 50 milligrams to 500 milligrams), or 1 microgram to 20 milligrams (e.g. 1 microgram to 10 milligrams, for example 0.1 milligram to 2 milligrams of active ingredient).
[0240] For oral compositions, unit dosage forms may contain from 1 mg to 2 g, more typically 10 mg to 1 g, for example 50 mg to 1 g, for example 100 mg to 1 g, of active compound.
[0241] The active compound will be administered to a patient (eg, a human or animal patient) in need thereof in an amount sufficient to achieve the desired therapeutic effect (effective amount). The precise amount of compound administered can be determined by a supervising physician according to standard procedures. Example
[0242] The invention will now be illustrated without limiting the invention by reference to specific embodiments described in the following examples.
[0243] Example 1-1 to Example 8-25
[0244] Some of the compounds of Example 1-1 to Example 8-25 shown in the following Table 1 have been prepared. The NMR and LCMS properties of the compounds and the methods used to prepare them are set forth in Table 3. The starting materials used for each of the examples are listed in Table 2.
[0245]
[0246]
[0247]
[0248] General Procedure
[0249] Where preparative routes are not included, the relevant intermediates are commercially available. Commercial reagents were used without further purification. Room temperature (rt) refers to about 20°C-27°C. Data were recorded at 400 MHz on a Bruker or Jeol instrument. 1HNMR spectra. Chemical shift values are expressed in parts per million (ppm), i.e. (δ)-values. The following abbreviations are used for the multiplicity of NMR signals: s = singlet, br = broad, d = doublet, t = triplet, q = quartet, quint = quintet, td = triplet of doublet, tt = triplet of triplet, qd = quartet of doublet, ddd = doublet of doublet of doublet, ddt = doublet of doublet of triplet, m = multiplet. Coupling constants are listed as J values measured in Hz. NMR and mass spectrometry results are corrected to take into account background peaks. Chromatography refers to column chromatography performed using 60-120 mesh silica gel and under nitrogen pressure (flash chromatography). TLC used to monitor the reaction refers to TLC runs using a specified mobile phase and silica gel F254 from Merck as the stationary phase. Microwave-mediated reactions were performed in a Biotage Initiator or CEM Discover microwave reactor.
[0250] LCMS analysis
[0251] LCMS analysis of the compounds was performed under electrospray conditions using the instrumentation and methods given in the table below:
[0252]
[0253]
[0254] The LCMS data in the Experimental section and Tables 2 and 3 are given in the following format: (Instrument system, Method): mass ion, retention time, UV detection wavelength.
[0255] Compound purification
[0256] Final purification of compounds was performed by preparative reverse phase HPLC, chiral HPLC or chiral SFC using the instrumentation and methods detailed below, where data are given in the following format: Purification Technique: [Phase (column description, column length x internal diameter, particle size), solvent flow, gradient - given as % of mobile phase B in mobile phase A (over time), mobile phase (A), mobile phase (B)].
[0257] Preparative HPLC purification:
[0258] Shimadzu LC-20AP Binary System with SPD-20A UV Detector
[0259] Chiral HPLC purification:
[0260] Shimadzu LC-20AP Binary System with SPD-20A UV Detector
[0261] Chiral SFC purification:
[0262] Waters SFC 200
[0263] Purification Method A
[0264] SFC: [(CHIRALPAK AD-H, 250×21 mm, 5 μm), 80 mL per min, mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in IPA:MeOH (50:50), isocratic (A:B) (85:15) (within 10 min)].
[0265] Purification method B
[0266] Preparative HPLC: [reversed phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 16 mL per min, gradient 5%–40% (within 35 min), 40% (within 2 min), 100% (within 2 min), then 100%–5% (within 4 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile].
[0267] Purification Method C
[0268] Preparative HPLC: [reversed phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 15 mL per min, gradient 20%–35% (in 30 min), 100% (in 2 min), then 100%–20% (in 2 min), mobile phase (A): 0.1% formic acid in water, (B) 100% acetonitrile].
[0269] Purification Method D
[0270] SFC: [(CHIRALPAK IB, 250×21 mm, 5 μm), 75 mL per min, mobile phase (A): 100% liquid CO 2 , (B): 0.1% diethylamine in MeOH, isocratic (A:B) (90:10) (within 8 min)].
[0271] Purification Method E
[0272] SFC: [(CHIRALCEL OX-H, 250×21 mm, 5 μm), 70 mL per min, mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in IPA:MeOH (50:50), isocratic (A:B) (75:25) (within 13 min)].
[0273] Purification Method F
[0274] Preparative HPLC: [reversed phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 18 mL per min, gradient 5%–65% (in 20 min), 100% (in 2 min), then 100%–5% (in 3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile].
[0275] Purification Method G
[0276] SFC: [(CHIRALPAK IC, 250×21 mm, 5 μm), 70 mL per min, mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in IPA, isocratic (A:B) (75:25) (within 20 min)].
[0277] Purification Method H
[0278] Preparative HPLC: [reversed phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 15 mL per min, gradient 5%–55% (in 18 min), 100% (in 2 min), then 100%–5% (in 3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile].
[0279] Purification Method I
[0280] SFC: [(CHIRALPAK AD-H, 250×21 mm, 5 μm), 70 mL per min, mobile phase (A): 100% liquid CO2, (B): 0.2% diethylamine in IPA:MeOH (50:50), isocratic (A:B) (75:25) (within 9 min)].
[0281] Purification method J
[0282] Preparative HPLC: [reversed phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 17 mL per min, gradient 0%–50% (within 33 min), 100% (within 2 min), then 100%–0% (within 2 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile].
[0283] Purification Method K
[0284] SFC: [(CHIRALPAK AD-H, 250×21 mm, 5 μm), 75 mL per min, mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in MeOH, isocratic (A:B) (85:15) (within 14.0 min)].
[0285] Purification method L
[0286] Preparative HPLC: [reversed phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 17 mL per min, gradient 35%–45% (in 17 min), 100% (in 2 min), then 100%–35% (in 2 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile].
[0287] Purification Method M
[0288] SFC: [(CHIRALCEL OX-H, 250×21 mm, 5 μm), 75 mL per min, mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in MeOH, isocratic (A:B) (85:15) (within 20 min)].
[0289] Purification Method N
[0290] Preparative HPLC: [reversed phase (X-BRIDGE C-18, 250×19 mm, 5 μm), 16 mL per min, gradient 25% (in 46 min), 100% (in 3 min), then 100%–25% (in 5 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.05% ammonia in water, (B) 100% acetonitrile].
[0291] Purification Method O
[0292] SFC: [(CHIRALPAK AD-H, 250×21 mm, 5 μm), 70 mL per min, mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in IPA:MeOH (50:50), isocratic (A:B) (75:25) (within 17.0 min)].
[0293] Purification Method P
[0294] Preparative HPLC: [reversed phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL per min, gradient 5%–20% (within 35 min), 100% (within 2 min), then 100%–5% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.05% ammonia in water, (B) 100% acetonitrile].
[0295] Purification Method Q
[0296] SFC: [(CHIRALPAK IB, 250×20 mm, 5 μm), 70 mL per min, mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in IPA:MeOH (50:50), isocratic (A:B) (85:15) (within 9 min)].
[0297] Purification Method R
[0298] Preparative HPLC: [reversed phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 13 mL per min, gradient 15%–40% (in 20 min), 100% (in 2 min), then 100%–15% (in 3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile].
[0299] Purification method S
[0300] SFC: [(CHIRALPAK AD-H, 250×21 mm, 5 μm), 80 mL per min, mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in MeOH, isocratic (A:B) (75:25) (within 8 min)].
[0301] Purification method T
[0302] Preparative HPLC: [reversed phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 16 mL per min, gradient 20%–30% (within 25 min), 30% (within 5 min), 100% (within 2 min), then 100%–20% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.05% ammonia in water, (B): 100% acetonitrile].
[0303] Purification Method U
[0304] Chiral HPLC [normal phase (CHIRALPAK AD-H 250×21 mm, 5 μm), 18 mL per min, mobile phase (A): 0.1% diethylamine in hexane, B) 0.1% diethylamine in IPA:MeOH (25:75), isocratic (A:B) (80:20) (within 25 min)].
[0305] Purification Method V
[0306] Preparative HPLC: [reversed phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 16 mL per min, gradient 10%–35% (within 30 min), 35% (within 14 min), 100% (within 2 min), then 100%–10% (within 2 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B): 100% acetonitrile].
[0307] Purification Method W
[0308] Chiral HPLC: [normal phase (CHIRALPAK AD-H 250×21 mm, 5 μm), 18 mL per min, mobile phase (A): 0.1% diethylamine in hexane, B) 0.1% diethylamine in IPA:MeOH (30:70), isocratic (A:B) (85:15) (within 20 min)].
[0309] Purification MethodX
[0310] Preparative HPLC: [reversed phase (X-BRIDGE C-18, 250×19 mm, 5 μm), 15 mL per min, gradient 10%–40% (in 25 min), 40% (in 5 min), 100% (in 2 min), then 100%–10% (in 4 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B): 100% acetonitrile].
[0311] Purification Method Y
[0312] Chiral HPLC [normal phase (CHIRALPAK AD-H 250×21 mm, 5 μm), 18 mL per min, mobile phase (A): 0.1% diethylamine in hexane, B) 0.1% diethylamine in IPA, isocratic (A:B) (90:10) (within 37 min)].
[0313] Purification method Z
[0314] Preparative HPLC: [reversed phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 15 mL per min, gradient 20%–50% (in 23 min), 100% (in 2 min), then 100%–20% (in 4 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile].
[0315] Purification Method AA
[0316] SFC: [(CHIRALPAK IB, 250×20 mm, 5 μm), 70 mL per min, mobile phase (A): 100% liquid CO 2 , (B): 0.1% diethylamine in MeOH, isocratic (A:B) (85:15) (within 7 min)].
[0317] Purification Method AB
[0318] Preparative HPLC: [reversed phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL per min, gradient 20%–45% (within 20 min), 100% (within 2 min), then 100%–20% (within 5 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile].
[0319] Purification Method AC
[0320] Chiral HPLC [normal phase (CHIRALPAK AD-H 250×21 mm, 5 μm), 18 mL per min, mobile phase (A): 0.1% diethylamine in hexane, B) 0.1% diethylamine in IPA:MeOH (25:75), isocratic (A:B) (80:20) (within 50 min)].
[0321] Purification Method AD
[0322] Preparative HPLC: [reversed phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL per min, gradient 0%–28% (within 25 min), 28% (within 5 min), 100% (within 2 min), then 100%–0% (within 3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.05% ammonia in water, (B) 100% acetonitrile].
[0323] Purification Method AE
[0324] SFC: [(CHIRALPAK IB, 250×20 mm, 5 μm), 70 mL per min, mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in IPA:MeOH (50:50), isocratic (A:B) (80:20) (within 10 min)].
[0325] Purification Method AF
[0326] Preparative HPLC: [reversed phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 15 mL per min, gradient 5%–27% (in 42 min), 27% (in 6 min), 100% (in 2 min), then 100%–5% (in 3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.05% ammonia in water, (B) 100% acetonitrile].
[0327] Purification Method AG
[0328] SFC: [(CHIRALPAK AD-H, 250×21 mm, 5 μm), 70 mL per min, mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in IPA:MeOH (50:50), isocratic (A:B) (70:30) (within 6 min)].
[0329] Purification Method AH
[0330] Preparative HPLC: [reversed phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 15 mL per min, gradient 15%–35% (within 20 min), 35% (within 3 min), 100% (within 2 min), then 100%–15% (within 4 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile].
[0331] Purification Method AI
[0332] SFC: [(CHIRALPAK IB, 250×20 mm, 5 μm), 70 mL per min, mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in IPA:MeOH (50:50), isocratic (A:B) (85:15) (within 8 min)].
[0333] Purification Method AJ
[0334] Preparative HPLC: [reversed phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 15 mL per min, gradient 0%–38% (in 28 min), 100% (in 2 min), then 100%-0% (in 3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile].
[0335] Purification Method AK
[0336] SFC: [(CHIRALPAK IB, 250×20 mm, 5 μm), 70 mL per min, mobile phase (A): 100% liquid CO2, (B): 0.1% ammonia in IPA:MeOH (50:50), isocratic (A:B) (88:12) (within 20 min)].
[0337] Purification Method AL
[0338] Preparative HPLC: [reversed phase (X SELECT PHENYL HEXYL, 250×19 mm, 5 μm), 15 mL per min, gradient 0%–40% (in 24 min), 40% (in 4 min), 100% (in 4 min), then 100%–0% (in 3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile].
[0339] Purification Method AM
[0340] SFC: [(CHIRALPAK AD-H, 250×21 mm, 5 μm), 70 mL per min, mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in IPA:MeOH (50:50), isocratic (A:B) (87:13) (within 12 min)].
[0341] Purification Method AN
[0342] Preparative HPLC: [reversed phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 13 mL per min, gradient 0%–30% (in 55 min), 30% (in 20 min), 100% (in 2 min), then 100%–0% (in 3 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.05% ammonia in water, (B) 100% acetonitrile].
[0343] Purification Method AO
[0344] SFC: [(CHIRALPAK IB, 250×20 mm, 5 μm), 80 mL per min, mobile phase (A): 100% liquid CO2, (B): 0.1% diethylamine in IPA:MeOH (50:50), isocratic (A:B) (85:15) (within 9 min)].
[0345] Purification Method AP
[0346] Preparative HPLC: [reversed phase (X-BRIDGE C-18, 250×19 mm, 5 μm), 10 mL per min, gradient 10%–70% (within 20 min), 70% (within 2 min), 100% (within 2 min), then 100%–10% (within 4 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile].
[0347] Purification method AQ
[0348] Preparative HPLC: [reversed phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 14 mL per min, gradient 15%–30% (in 35 min), 70% (in 16 min), 100% (in 2 min), then 100%–15% (in 6 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile].
[0349] Purification Method AR
[0350] Preparative HPLC: [reversed phase (X-BRIDGE C-8, 250×19 mm, 5 μm), 16 mL per min, gradient 20% (in 60 min), 100% (in 2 min), then 100%–20% (in 5 min), mobile phase (A): 5 mM ammonium bicarbonate + 0.1% ammonia in water, (B) 100% acetonitrile].
[0351] abbreviation
[0352] atm. = atmosphere
[0353] conc.=thick
[0354] DCM = dichloromethane
[0355] DMF = dimethylformamide
[0356] ES(I)=Electrospray ionization
[0357] EtOAc = Ethyl acetate
[0358] h = hours
[0359] H2O = water
[0360] HCl = Hydrogen chloride, hydrochloric acid
[0361] HPLC = High Performance Liquid Chromatography
[0362] IPA = Isopropyl alcohol (propan-2-ol)
[0363] LC = Liquid Chromatography
[0364] MeOH = methanol
[0365] min(s)=minutes
[0366] MS = mass spectrometry
[0367] nm = nanometer
[0368] NMR = Nuclear Magnetic Resonance
[0369] SFC = Supercritical Fluid Chromatography
[0370] TEA = triethylamine
[0371] TFA = trifluoroacetic acid
[0372] TLC = Thin Layer Chromatography
[0373] The prefixes n-, s-, i-, t-, and tert- have their usual meanings: normal, secondary, iso, and tertiary.
[0374] Synthesis of intermediates:
[0375] Route 1
[0376] A typical procedure for the preparation of ketones, as exemplified by the preparation of the intermediate 3-ethyl 7-oxo-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate
[0377]
[0378] Tert-butyl 7-oxo-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate (Intermediate 1) (200 mg, 0.83 mmol) was dissolved in DCM (8 mL) and the solution was cooled down to 0° C. TFA (1 mL) was added dropwise and the resulting reaction mixture was stirred at 25° C. for 6 h. The solvent was removed in vacuo and the residue was purified by trituration with diethyl ether (3×1 mL) to give crude 3-oxa-9-azabicyclo[3.3.1]nonan-7-one trifluoroacetate (115 mg, 98%) as a white solid.
[0379] LCMS (System 4, Method C): m / z 142 (M+H)+ (ESI+ve), at 0.59–0.80 min, 202 nm.
[0380] Triethylamine (0.3 mL, 2.44 mmol) was added to a solution of crude 3-oxa-9-azabicyclo[3.3.1]nonan-7-one trifluoroacetate (115 mg, 0.82 mmol) in DCM (10 mL), and the mixture was cooled to 0 ° C and stirred for 20 min. Ethyl chloroformate (Intermediate 2) (0.13 mL, 1.22 mmol) was then added dropwise at 0 ° C, and the resulting reaction mixture was stirred at 25 ° C for 1 h. The solvent was removed in vacuo, and the residue was partitioned between H2O (80 mL) and EtOAc (60 mL). The aqueous layer was further extracted with EtOAc (2×60 mL), and the combined organic layers were dried (Na 2 SO 4 ) and the solvent removed in vacuo to give ethyl 7-oxo-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate (Intermediate 3) (170 mg, 98%) as a gum which was used without further purification.
[0381] The data for Intermediate 3 are in Table 2.
[0382] Route 2
[0383] A typical procedure for the preparation of piperidines, as exemplified by the preparation of intermediate 9—2-methoxy-6-(piperidin-4-yl)pyridine hydrochloride
[0384]
[0385] Tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (Intermediate 7) (395 mg, 1.28 mmol) and CsCO (1.03 g, 3.19 mmol) were added to a solution of 2-iodo-6-methoxypyridine (Intermediate 8) (300 mg, 1.28 mmol) in 1,4-dioxane (10 mL), and the resulting mixture was degassed under a nitrogen atmosphere for 20 min. (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (Xantphos, 36 mg, 0.06 mmol) and palladium(II) acetate (29 mg, 0.13 mmol) were added, and the resulting reaction mixture was stirred at 80° C. for 18 h. The solvent is removed in a vacuum, and the residue is distributed between H2O (80mL) and EtOAc (60mL). The aqueous layer is further extracted with EtOAc (60mL), and the combined organic layer is dried (Na2SO4), and the solvent is removed in a vacuum. The residue is purified by column chromatography (normal phase neutral activated alumina, 10% to 12% EtOAc in hexane) to give 6-methoxy-3', 6'-dihydro-2,4'-bipyridine-1' (2'H)-tert-butyl formate (310mg, 84%) as a jelly.
[0386] LCMS (System 3, Method D): m / z 291 (M+H) + (ESI+ve), at 5.73min, 202nm.
[0387] 10% palladium on carbon (50% moisture, 100mg) is added to a solution of 6-methoxy-3', 6'-dihydro-2,4'-bipyridine-1' (2'H)-tert-butyl formate (300mg, 1.03mmol) in MeOH (20mL), and the resulting mixture is stirred at 70 ° C for 40h under an atmosphere of hydrogen (1 atmosphere). The reaction mixture is filtered through diatomaceous earth, and the filtrate is concentrated in vacuo. The crude product is ground with pentane to give tert-butyl 4- (6-methoxypyridin-2-yl) piperidine-1-formate (240mg, 79%) as a jelly.
[0388] LCMS (System 3, Method D): m / z 293 (M+H) + (ESI+ve), at 5.05min, 202nm.
[0389] Tert-butyl 4-(6-methoxypyridin-2-yl)piperidine-1-carboxylate (240 mg, 0.82 mmol) was dissolved in 1,4-dioxane (5 mL) and cooled to 0° C. A solution of HCl in 1,4-dioxane (4M, 5 mL) was added dropwise, and the resulting reaction mixture was stirred at 25° C. for 8 h. The solvent was removed in vacuo, and the residue was purified by trituration with pentane (3×2 mL) to give 2-methoxy-6-(piperidin-4-yl)pyridine hydrochloride (Intermediate 9) (130 mg, 82%) as a solid.
[0390] The data for intermediate 9 are in Table 2.
[0391] Route 3
[0392] A typical procedure for the preparation of piperidines, as exemplified by the preparation of intermediate 21 - N-(2-methylpropyl)-N-(piperidin-4-yl)acetamide hydrochloride
[0393]
[0394] tert-Butyl 4-oxopiperidin-1-carboxylate (Intermediate 19) (5.0 g, 25.1 mmol) was dissolved in MeOH (50 mL) and 2-methylpropan-1-amine (Intermediate 20) (1.83 g, 25.1 mmol) was added. 10% palladium hydroxide on carbon (50% moisture, 500 mg) was then added and the resulting reaction mixture was stirred at 25 ° C for 17 h under an atmosphere of hydrogen (1 atmosphere). The mixture was filtered through celite and the filtrate was concentrated in vacuo to give tert-butyl 4-[(2-methylpropyl)amino]piperidine-1-carboxylate (5.0 g, 78%) as a gum.
[0395] LCMS (System 3, Method D): m / z 257 (M+H) + (ESI+ve), at 3.39min, 202nm.
[0396] Tert-butyl 4-[(2-methylpropyl)amino]piperidine-1-carboxylate (5.0 g, 19.5 mmol) was dissolved in DCM (50 mL) and cooled to 0°C. Triethylamine (2.7 mL, 19.5 mmol) was added dropwise at 0°C-5°C, and the mixture was stirred at 0°C-5°C for 10 min. Acetic anhydride (2.3 g, 23.4 mmol) was then added dropwise at 0°C-5°C, and the resulting reaction mixture was stirred at 25°C for 2 h. The solvent was removed in vacuo to give tert-butyl 4-[acetyl(2-methylpropyl)amino]piperidine-1-carboxylate (5.5 g, 89%) as a liquid.
[0397] LCMS (System 3, Method D): m / z 597 (2M+H) + ,284(M-Me+H) + (ESI+ve), at 4.03min, 202nm.
[0398] Tert-butyl 4-[acetyl(2-methylpropyl)amino]piperidine-1-carboxylate (5.0 g, 15.8 mmol) was slowly dissolved in a solution of HCl in 1,4-dioxane (4M, 50 mL), and the resulting mixture was stirred at 25° C. for 16 h. The solvent was removed in vacuo, and the residue was purified by trituration with diethyl ether (3×250 mL) to give N-(2-methylpropyl)-N-(piperidin-4-yl)acetamide hydrochloride (Intermediate 21) (3.0 g, 88%) as a gum.
[0399] The data for intermediate 21 are in Table 2.
[0400] Route 4
[0401] A typical procedure for the preparation of piperidines, as exemplified by the preparation of intermediate 23 - N-(2,2-dimethylpropyl)-N-(piperidin-4-yl)acetamide trifluoroacetate
[0402]
[0403] Tert-butyl 4-oxopiperidine-1-carboxylate (intermediate 19) (3.0 g, 15.0 mmol), 2,2-dimethylpropan-1-amine (intermediate 22) (1.5 g, 18 mmol), triethylamine (6.2 mL, 45 mmol) and ZnCl2 (0.7 mL, 0.07 mmol) were dissolved in MeOH (30 mL) and the reaction mixture was stirred at 65 ° C for 6 h. NaBH3CN (2.8 g, 45 mmol) was then added to the reaction mixture in batches at 0 ° C. The resulting reaction mixture was stirred at 25 ° C for 17 h. The solvent was removed in vacuo and the residue was partitioned between H2O (100 mL) and DCM (80 mL). The aqueous layer was further extracted with DCM (2 x 80 mL) and the combined organic phases were dried (Na2SO4) and concentrated in vacuo to give tert-butyl 4-[(2,2-dimethylpropyl)amino]piperidine-1-carboxylate (3.5 g, 88%) as a yellow gum.
[0404] LCMS (System 3, Method D): m / z 271 (M+H) + (ESI+ve), at 4.22min, 202nm.
[0405] Tert-butyl 4-[(2,2-dimethylpropyl)amino]piperidine-1-carboxylate (3.5 g, 12 mmol) and triethylamine (5.3 mL, 30 mmol) were dissolved in DCM (20 mL) under nitrogen and stirred at 0° C. for 10 min. Acetyl chloride (1.3 mL, 19 mmol) was then added dropwise at 0° C.-10° C., and the mixture was stirred at 25° C. for 2 h. The reaction mixture was partitioned between H2O (150 mL) and EtOAc (120 mL). The aqueous layer was further extracted with EtOAc (2 x 120 mL), and the combined organic phases were dried (Na2SO4) and concentrated in vacuo to give the crude product, which was purified by column chromatography (normal phase silica, 0% to 20% EtOAc in hexanes) to give tert-butyl 4-[acetyl(2,2-dimethylpropyl)amino]piperidine-1-carboxylate (3.1 g, 76%) as a yellow gum.
[0406] LCMS (System 3, Method D): m / z 313 (M+H) + (ESI+ve), at 4.41min, 202nm.
[0407] To a solution of tert-butyl 4-[acetyl(2,2-dimethylpropyl)amino]piperidine-1-carboxylate (3.1 g, 9 mmol) in DCM (14 mL) was added TFA (7.0 mL) dropwise at 0°C. The reaction was stirred at 25°C for 6 h. The solvent was removed in vacuo, and the residue was purified by trituration with pentane (3 x 1 mL) to give N-(2,2-dimethylpropyl)-N-(piperidin-4-yl)acetamide trifluoroacetate (Intermediate 23) (1.8 g, 86%) as a yellow gum.
[0408] The data for intermediate 23 are in Table 2.
[0409] Route 5
[0410] A typical procedure for the preparation of piperidines, as exemplified by the preparation of intermediate 33—1-(piperidin-4-yl)azepan-2-one hydrochloride
[0411]
[0412] tert-Butyl 4-aminopiperidine-1-carboxylate (intermediate 31) (5.0 g, 25.0 mmol) was dissolved in DCM (50 mL) and triethylamine (4.17 mL, 30.0 mmol) was added. The mixture was cooled to 0 ° C, and then 6-bromohexanoyl chloride (intermediate 32) (6.4 g, 30.0 mmol) was added. The resulting reaction mixture was stirred at 25 ° C for 2 h, and then the mixture was partitioned between H2O (100 mL) and EtOAc (100 mL). The aqueous layer was further extracted with EtOAc (2×25 mL), the combined organic layers were dried (Na2SO4), and the solvent was removed in vacuo to give tert-butyl 4-[(6-bromohexanoyl)amino]piperidine-1-carboxylate (5.5 g, 78%) as a solid.
[0413] LCMS (System 3, Method D): m / z 375 / 377 (MH) - ,(ESI-ve),at 4.10min,202nm.
[0414] 4-[(6-bromohexanoyl)amino]piperidine-1-carboxylic acid tert-butyl ester (5.0 g, 13.2 mmol) was dissolved in DMF (100 mL) and a NaH suspension (60%, 638 mg, 15.9 mmol) was added in batches at 0°C-5°C in mineral oil. The reaction mixture was then heated to 80°C and stirred for 2 h. The reaction mixture was partitioned between H2O (100 mL) and EtOAc (100 mL), and the aqueous layer was further extracted with EtOAc (2×25 mL). The combined organic layers were dried (Na2SO4), the solvent was removed in vacuo, and the crude product was purified by column chromatography (silica 60-120 mesh, 0% to 18% EtOAc in hexane) to give tert-butyl 4-(2-oxoazepan-1-yl)piperidine-1-carboxylate (1.0 g, 25%) as a gum.
[0415] LCMS (System 3, Method D): m / z 297 (M+H) + ,241(M-56+H) + (ESI+ve), at 3.73min, 202nm.
[0416] Tert-butyl 4-(2-oxoazepan-1-yl)piperidine-1-carboxylate (1.0 g, 3.37 mmol) was dissolved in a solution of HCl in 1,4-dioxane (4M, 10 mL) and the resulting reaction mixture was stirred at 25° C. for 16 h. The solvent was removed in vacuo and the residue was purified by trituration with diethyl ether (3×250 mL) to give 1-(piperidin-4-yl)azepan-2-one hydrochloride (Intermediate 33) (450 mg, 68%) as a gum.
[0417] The data for intermediate 33 are in Table 2.
[0418] General synthesis procedure:
[0419] Route A
[0420] A typical procedure for preparing piperidines, as exemplified by Example 1-1 - Preparation of ethyl 7-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate
[0421]
[0422] 4-(1H-pyrazol-1-yl)piperidine (Intermediate 4) (150 mg, 0.9 mmol), ethyl 7-oxo-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate (Intermediate 3) (232 mg, 1.0 mmol), triethylamine (499 mg, 4.9 mmol) and zinc chloride solution (1M in diethyl ether, 0.03 mL, 0.03 mmol) were dissolved in MeOH (5 mL) under nitrogen and stirred at 50-60° C. for 8 h. After 8 h, NaBH3CN (184 mg, 2.9 mmol) was added portionwise at 0-10° C., and the resulting mixture was stirred at 50-60° C. until the reaction was complete. The reaction mixture was partitioned between H2O (20 mL) and EtOAc (30 mL), and the aqueous layer was further extracted with EtOAc (2×30 mL). The combined organic layers were dried (Na2SO4) and the solvent was removed in vacuo to give the crude product, which was purified using Purification Method A to give ethyl 7-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate, Example 1-1 Isomer 1 as a gum (11 mg, 4%) and ethyl 7-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate, Isomer 2 as a gum (39 mg, 12%).
[0423] The data of Example 1-1 Isomer 1 is in Table 3.
[0424] Route B
[0425] A typical procedure for the preparation of pyridones from methoxypyridines, as exemplified by Example 2-3 - Preparation of ethyl 7-[4-(2-oxo-1,2-dihydropyridin-3-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate
[0426]
[0427] To a stirred solution of ethyl 7-[4-(2-methoxypyridin-3-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate (Example 2-2) (0.09 g, 2.31 mmol) in 1,4-dioxane (1.5 mL) as a mixture of isomers, H2O (1 mL) and concentrated HCl (1 mL) were added, and the reaction mixture was then stirred at 100° C. for 16 h. The solvent was removed in vacuo, the residue was partitioned between H2O (2 mL) and EtOAc (10 mL), and the aqueous layer was further extracted with EtOAc (2×5 mL). The combined organic layers were dried (Na2SO4), the solvent was removed in vacuo, and the residue was purified using Purification Method H followed by Purification Method I to give ethyl 7-[4-(2-oxo-1,2-dihydropyridin-3-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate, Example 2-3 Isomer 1 as a gum (2 mg, 2%) and ethyl 7-[4-(2-oxo-1,2-dihydropyridin-3-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate, Example 2-3 Isomer 2 as a gum (20 mg, 23%).
[0428] The data of Isomer 1 and Isomer 2 of Examples 2-3 are in Table 3.
[0429] Route C
[0430] A typical procedure for the preparation of piperidine-4-carboxamide, as exemplified by Example 7-1 - Preparation of ethyl 7-{4-[(1-methylcyclobutyl)carbamoyl]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate
[0431]
[0432] Piperidine-4-carboxylic acid ethyl ester (intermediate 34) (1.0 g, 6.36 mmol), 7-oxo-3-oxa-9-azabicyclo [3.3.1] nonane-9-carboxylic acid ethyl ester (intermediate 3) (1.30 g, 6.36 mmol), triethylamine (2.7 mL, 19.1 mmol) and ZnCl2 (86 mg, 0.63 mmol) were dissolved in MeOH (20 mL), and the mixture was stirred at 70 ° C for 8 h. The reaction mixture was then cooled to 0 ° C, and NaBH3CN (1.20 g, 19.1 mmol) was added in batches. The resulting mixture was stirred at 70 ° C for 150 h, and then the solvent was removed in vacuo. The residue was distributed between H2O (150 mL) and EtOAc (120 mL), and the aqueous layer was further extracted with EtOAc (2×120 mL). The combined organic layers were dried (Na2SO4), the solvent was removed in vacuo, and the residue was purified by column chromatography (normal phase neutral activated alumina, 20% to 80% EtOAc in hexanes) to give ethyl 7-[4-(ethoxycarbonyl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate (800 mg, 36%) as a gum.
[0433] LCMS (System 3, Method D): m / z 341 (M-14+H) + ,(ESI+ve),at 2.87min,202nm.
[0434] 1-Methylcyclobutane-1-amine hydrochloride (intermediate 35) (102 mg, 0.85 mmol) was dissolved in toluene (10 mL), triethylamine (0.3 mL, 1.69 mmol) was added, and the mixture was cooled to -10 ° C. Trimethylaluminum solution (2M, 0.8 mL, 1.69 mmol) in toluene was added, and the reaction mixture was stirred at -10 ° C for 20 min. Then 7-[4-(ethoxycarbonyl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester (200 mg, 0.56 mmol) was added at -10 ° C, and the resulting mixture was stirred at 80 ° C for 18 h. The solvent was removed in vacuo, and the residue was partitioned between H2O (80 mL) and DCM (60 mL). The aqueous layer was further extracted with DCM (2 x 60 mL), and the combined organic layers were dried (Na2SO4), and the solvent removed in vacuo. The residue (230 mg) was purified using Purification Method AH followed by Purification Method AI to give ethyl 7-{4-[(1-methylcyclobutyl)carbamoyl]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate, Example 7-1 Isomer 1 (6 mg, 3%) as a gum and ethyl 7-{4-[(1-methylcyclobutyl)carbamoyl]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate, Example 7-1 Isomer 2 (23 mg, 10%) as a gum.
[0435] The data of Isomer 1 and Isomer 2 of Example 7-1 are in Table 3.
[0436] Table 2 – Starting materials and intermediates
[0437]
[0438]
[0439]
[0440]
[0441]
[0442]
[0443]
[0444]
[0445]
[0446]
[0447]
[0448]
[0449] Biological activity
[0450] Example A
[0451] Phospho-ERK1 / 2 assay
[0452] Functional assays were performed using Alphascreen Surefire phospho-ERK1 / 2 assays (Crouch & Osmond, Comb. Chem. High Throughput Screen, 2008). ERK1 / 2 phosphorylation is a downstream result of activation of both Gq / 11 and Gi / o protein-coupled receptors, making it highly suitable for evaluating M1, M3 receptors (Gq / 11 coupling) and M2, M4 receptors (Gi / o coupling), rather than using different assay formats for different receptor subtypes. CHO cells stably expressing human muscarinic M1, M2, M3 or M4 receptors were plated (25K / well) into MEM-α+10% dialyzed FBS on 96-well tissue culture plates. After adhesion, cells were serum starved overnight. Agonist stimulation was performed by adding 5 μL of agonist to cells for 5 min (37° C.). The culture medium was removed and 50 μL of lysis buffer was added. After 15 min, 4 μL of sample was transferred to a 384-well plate and 7 μL of detection mix was added. The plate was incubated in the dark with gentle agitation for 2 h and then read on a PHERAstar plate reader. pEC was calculated from the data obtained for each receptor subtype. 50 and E max The values are given in Table 4 below.
[0453] For the vast majority of embodiments, there are at least two diastereomers, and unless otherwise stated, these diastereomers have been separated using the techniques of reversed-phase HPLC, chiral HPLC or chiral SFC. The isomer distribution (isomer 1, isomer 2, etc.) is based on the retention time of the compound using the separation technique performed in the final purification step. Implicitly, this can be a reversed-phase HPLC retention time, a chiral HPLC retention time or a chiral SFC retention time, and the retention time will vary due to the compound.
[0454] Analytical data for the active isomers are reported in Table 3. Data for several weakly active compounds are included in Table 4 to highlight the absolute stereochemical preference.
[0455]
[0456]
[0457]
[0458] Equivalent solutions
[0459] The foregoing examples are presented for the purpose of illustrating the present invention, and should not be construed as imposing any limitation on the scope of the present invention. It will be readily apparent that many modifications and changes may be made to the specific embodiments of the present invention described above and illustrated in the examples, without departing from the principle as basis of the present invention. All such modifications and changes are intended to be included by the application.
Claims
1. A compound of formula (1): or a pharmaceutically acceptable salt thereof, in: R 1 Selected from NR 5 R 6 ;CONR 8 R 9 ; an optionally substituted 5- or 6-membered heteroaromatic ring containing 1 or 2 nitrogen atoms, wherein the optional substituents are selected from C 1 -C 3 Alkyl, C 1 -C 3 alkoxy, halogen, cyano, oxo, hydroxyl and amino; R 2 is selected from hydrogen and cyano; Or, R 1 and R 2 Together they form a part selected from: and R 4 Is H or C 1-6 alkyl; R 5 For COCH 3 ; R 6 Selected from non-aromatic C optionally substituted by an optionally substituted phenyl ring 1-6 A hydrocarbon group wherein the optional substituents on the phenyl ring are selected from C 1 -C 3 Alkyl, C 1 -C 3 Alkoxy, halogen, cyano, oxo, hydroxyl and amino, among which C 1 -C 3 Alkyl or C 1 -C 3 The alkoxy groups are each optionally substituted with halogen, cyano, oxo, hydroxy or amino; R 8 is hydrogen or non-aromatic C 1-6 hydrocarbon groups; And R 9 Non-aromatic C 1-6 Hydrocarbon group.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is an optionally substituted 5- or 6-membered aromatic ring containing 1 or 2 nitrogen heteroatoms, wherein the optional substituents are selected from C 1 -C 3 Alkyl, C 1 -C 3 alkoxy, halogen, cyano, oxo, hydroxy or amino.
3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 YesNR 5 R 6 .
4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Together they form a part selected from: and 5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 It is CONR 8 R 9 .
6. The compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein R 8 It's hydrogen.
7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 It's H.
8. A compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, wherein R 4 Selected from methyl and ethyl.
9. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from: 7-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-[4-(4-chloro-1H-pyrazol-1-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-[4-(4-methyl-1H-pyrazol-1-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-[4-(6-methoxypyridin-2-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-[4-(2-methoxypyridin-3-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-[4-(2-oxo-1,2-dihydropyridin-3-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-[4-cyano-4-(pyridin-2-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-{4-[(2R)-4,4-difluoro-2-(hydroxymethyl)pyrrolidin-1-yl]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-(6-Azaspiro[2.5]octan-6-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester 7-(3-oxo-2,8-diazaspiro[4.5]dec-8-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-(2-oxo-1-oxa-3,8-diazaspiro[4.5]dec-8-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-(4-ethyl-2-oxo-1-oxa-3,8-diazaspiro[4.5]dec-8-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-(2-oxo-1,2-dihydro-1'H-spiro[indole-3,4'-piperidinyl]-1'-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-{4-[Acetyl(2-methylpropyl)amino]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-{4-[Acetyl(2,2-dimethylpropyl)amino]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-(4-{acetyl[(1-methylcyclopropyl)methyl]amino}piperidin-1-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-(4-{acetyl[(1-methylcyclobutyl)methyl]amino}piperidin-1-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-{4-[Acetyl(benzyl)amino]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-(2-oxo-1,4'-bipiperidin-1'-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-[4-(2-oxoazepan-1-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-{4-[(1-methylcyclobutyl)carbamoyl]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-{4-[(2-methylpropyl)carbamoyl]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-{4-[(cyclobutylmethyl)carbamoyl]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-[4-(Azepan-1-ylcarbonyl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid ethyl ester; 7-(4-(N-((1-methylcyclobutyl)methyl)acetylamino)piperidin-1-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-(4-(N-benzylacetylamino)piperidin-1-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-[4-(4-chloro-1H-pyrazol-1-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-[4-(4-methyl-1H-pyrazol-1-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-[4-(6-methoxypyridin-2-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-[4-(2-methoxypyridin-3-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-[4-(2-oxo-1,2-dihydropyridin-3-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-[4-cyano-4-(pyridin-2-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-{4-[(2R)-4,4-difluoro-2-(hydroxymethyl)pyrrolidin-1-yl]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-(6-azaspiro[2.5]octan-6-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-(3-oxo-2,8-diazaspiro[4.5]dec-8-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-(2-oxo-1-oxa-3,8-diazaspiro[4.5]dec-8-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-(4-ethyl-2-oxo-1-oxa-3,8-diazaspiro[4.5]dec-8-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-(2-oxo-1,2-dihydro-1'H-spiro[indole-3,4'-piperidinyl]-1'-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-{4-[Acetyl(2-methylpropyl)amino]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-{4-[Acetyl(2,2-dimethylpropyl)amino]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-(4-{acetyl[(1-methylcyclopropyl)methyl]amino}piperidin-1-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-(4-{acetyl[(1-methylcyclobutyl)methyl]amino}piperidin-1-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-(2-oxo-1,4'-bipiperidin-1'-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-[4-(2-oxoazepan-1-yl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-{4-[(1-methylcyclobutyl)carbamoyl]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-{4-[(2-methylpropyl)carbamoyl]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; 7-{4-[(cyclobutylmethyl)carbamoyl]piperidin-1-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; and 7-[4-(azepan-1-ylcarbonyl)piperidin-1-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid methyl ester; or a pharmaceutically acceptable salt thereof. 10 . A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
11. Use of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating cognitive impairment or psychotic disorder, or for treating acute pain, chronic pain, neuropathic pain or inflammatory pain or for alleviating the severity of acute pain, chronic pain, neuropathic pain or inflammatory pain.
12. The use according to claim 11, wherein the cognitive disorder is Alzheimer's disease.
13. The use according to claim 11, wherein the cognitive disorder is Lewy body dementia.
14. The use according to claim 11, wherein the cognitive disorder is schizophrenia.
15. The use according to claim 11, wherein the cognitive disorder is bipolar disorder.
Citation Information
Patent Citations
Bicyclic aza compounds as muscarinic M1 receptor agonists
CN104640851A
Muscarinic receptor agonists
CN106659719A
Spirocyclic compounds as agonists of the muscarinic m1 receptor and / or m4 receptor
CN107406449A
Muscarinic agonists
CN107949384A
Muscarinic agonists
CN107949558A
